

Hanne M. Lindegaard  
Klinisk Institut  
KI, OUH, Forskningsenhed for Reumatologi (Odense)  
E-mail: hlindegaard@health.sdu.dk, hanne.lindegaard@rsyd.dk



## Kvalifikationer

Biostatistical Methods in Health Research  
2011  
Project Management. University of Southern Denmark  
2010  
Board Certified in Internal Medicine:Rheumatology  
2006  
PhD  
2002  
MD, Aarhus University  
1991

## Ansættelse

Chief Physician, Department of Rheumatology, Internal Medicine C, Odense University Hospital  
September 2007 -  
Training responsible physician  
April 2008 - August 2013  
General manager of The Clinical Trial Unit, Department of Rheumatology, OUH  
September 2012 -  
Associate Professor Rheumatology, University of Southern Denmark - SDU  
January 2008 -  
Consultant / Research (50/50), Department of Rheumatology, Odense University Hospital / RSD Foundation  
December 2008 - May 2010  
Consultant / Research (50/50), Department of Rheumatology, Odense University Hospital / OUH Foundation  
Visiting Researcher, SDU  
January 1998 - December 2006

## Administrative experience

The Danish College of Rheumatology representative in the Danish Medical Society  
March 2007 - March 2009

YR representative of the central evaluation committee Internal Medicine: Rheumatology  
2004 - 2006

Representative of junior doctors in the regional education committee rheumatology, southern part of Denmark  
2003 - 2007

Board member of Young Rheumatologists  
March 2003 - March 2007

Junior doctor council President, Gråsten Rheumatism Hospital.  
September 2003 - August 2004

## Teaching experience

University of Southern Denmark - SDU Odense. Medicine  
2006 -  
Censor, Faculty of Medicine - KU  
2018 -  
University of Southern Denmark - SDU Esbjerg. Pathology and Public Health  
2007 - 2009  
Human Pathophysiology, University of Southern Denmark - SDU. Musculoskeletal system  
1999 - 2000  
Physiotherapy School in Odense

1996 - 1997

## Board memberships

Member of "Studienævnet for medicin" - SDU

2017 -

Member of research committee the Danish college of Rheumatology

2012 -

Member of "Medicinrådet" steering committee Danish Regions (appointed by the Counsel in the south region)  
March 2018 -

Chairman of RADS steering committee Danish Regions (appointed by the Danish college of Rheumatology)

September 2016 - March 2017

Member om RADS steering committee Danish Regions (appointed by the Counsel in the south region)

2009 - August 2016

Chairman Board of Education Internal Medicine: Rheumatology

March 2011 - August 2013

Board member of DANBIO steering committee (appointed by the Counsel in the south region)

2010 - 2016

Expert Legal Council

June 2008 - August 2014

## Research areas

Markers of connective tissue metabolism in inflammatory conditions.

Rheumatoid arthritis.

Eosinophilia in malignant and inflammatory conditions.

## GCP experience

CIMESTRA, HUMAX-CD4 (Genmab), OPERA, ACTFast, DANACT, SYK study and Lilly JAK study, Novartis IL-1-I (Measure/Future), Abbvie JAK study (NEXT, Combine), Nordstar, Imagine, Online-Course GCP and clinical pharmaceutical research.

## Publikationer

### **Long-Term efficacy of a 2-year MRI treat-To-Target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial**

Møller-Bisgaard, S., Hørslev-Petersen, K., Ørnberg, L. M., Ejbjerg, B., Hetland, M. L., Møller, J. M., Nielsen, S. M., Glinatsi, D., Boesen, M., Stengaard-Pedersen, K., Madsen, O. R., Jensen, B., Villadsen, J. A., Hauge, E. M., Hendricks, O., Lindegaard, H., Krogh, N. S., Jurik, A. G., Thomsen, H. & Christensen, R. & 1 flere, Østergaard, M., 15. mar. 2024, I: RMD Open. 10, 1, e003945.

### **The impact of an ultrasound atlas for scoring salivary glands in primary Sjögren's syndrome: a pilot study**

Schmidt, N. S., Fana, V., Danielsen, M. A., Lindegaard, H. M., Voss, A., Horn, H. C., Knudsen, J. B., Byg, K.-E., Morillon, M. B., Just, S. A., Døhn, U. M. & Terslev, L., dec. 2023, I: Clinical Rheumatology. 42, 12, s. 3275-3281

### **Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial**

Østergaard, M., Van Vollenhoven, R. F., Rudin, A., Hetland, M. L., Heiberg, M. S., Nordström, D. C., Nurmohamed, M. T., Gudbjornsson, B., Ørnberg, L. M., Bøyesen, P., Lend, K., Hørslev-Petersen, K., Uhlig, T., Sokka, T., Grondal, G., Krabbe, S., Lindqvist, J., Gjørtsson, I., Glinatsi, D. & Kapetanovic, M. C. & 26 flere, Aga, A. B., Faustini, F., Parmanne, P., Lorenzen, T., Giovanni, C., Back, J., Hendricks, O., Vedder, D., Rannio, T., Grenholm, E., Ljoså, M. K., Brodin, E., Lindegaard, H., Söderbergh, A., Rizk, M., Kastbom, A., Larsson, P., Uhrenholt, L., Just, S. A., Stevens, D. J., Bay Laurbjerg, T., Bakland, G., Olsen, I. C., Haavardsholm, E. A., Lampa, J. & NORD-STAR Study Group, okt. 2023, I: Annals of the Rheumatic Diseases. 82, 10, s. 1286-1295

### **Anti-IL17A in a pregnant patient with PsA: a case report**

Graversgaard, C., Hendricks, O., Lindegaard, H. M. & Schreiber, K., 23. aug. 2023, I: Scandinavian Journal of Rheumatology. 52, suppl. 131, s. 113-114 PP54.

### **Anti-IL17A in a pregnant patient with PsA: a case report**

Graversgaard, C., Hendricks, O., Lindegaard, H. M. & Schreiber, K., aug. 2023.

**Five-year follow-up of a 2-year MRI treat-to-target strategy on radiographic damage progression in rheumatoid arthritis patients in clinical remission: The imagine-more study**

Møller-Bisgaard, S., Hørslev-Petersen, K., Ørnbjerg, L. M., Ejbjerg, B. J., Hetland, M. L., Møller, J. M., Christensen, R., Nielsen, S. M., Glinatski, D., Boesen, M., Stengaard-Pedersen, K., Madsen, O., Jensen, B., Villadsen, J. A., Hauge, E. M., Hendricks, O., Lindegaard, H. M., Krogh, N. S., Jurik, A. G. & Thomsen, H. & 1 flere, Østergaard, M., jun. 2023, I: *Annals of the Rheumatic Diseases*. 82, suppl. 1, s. 235-236 POS0052.

**The multidisciplinary approach to eosinophilia**

Thomsen, G. N., Christoffersen, M. N., Lindegaard, H. M., Davidsen, J. R., Hartmeyer, G. N., Assing, K., Mortz, C. G., Martin-Iguacel, R., Møller, M. B., Kjeldsen, A. D., Havelund, T., El Fassi, D., Broesby-Olsen, S., Maiborg, M., Johansson, S. L., Andersen, C. L., Vestergaard, H. & Bjerrum, O. W., 18. maj 2023, I: *Frontiers in Oncology*. 13, 24 s., 1193730.

**Salivary gland ultrasound is associated with the presence of autoantibodies in patients with Sjögren's syndrome: A Danish single-centre study**

Schmidt, N. S., Voss, A., Nilsson, A. C., Terslev, L., Just, S. A. & Lindegaard, H. M., dec. 2022, I: *PLOS ONE*. 17, 12, e0265057.

**Ultrasound joint examination by an automated system versus by a rheumatologist: from a patient perspective**

Frederiksen, B. A., Schousboe, M., Terslev, L., Iversen, N., Lindegaard, H., Savarimuthu, T. R. & Just, S. A., 8. aug. 2022, I: *Advances in Rheumatology*. 62, 10 s., 30.

**Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial**

Møller-Bisgaard, S., Hørslev-Petersen, K., Ejbjerg, B., Hetland, M. L., Christensen, R., Ørnbjerg, L. M., Glinatsi, D., Møller, J. M., Boesen, M., Stengaard-Pedersen, K., Madsen, O. R., Jensen, B., Villadsen, J. A., Hauge, E. M., Bennett, P., Hendricks, O., Asmussen, K., Kowalski, M., Lindegaard, H. & Bliddal, H. & 7 flere, Krogh, N. S., Ellingsen, T., Nielsen, A. H., Larsen, L., Jurik, A. G., Thomsen, H. S. & Østergaard, M., jul. 2022, I: *Scandinavian Journal of Rheumatology*. 51, 4, s. 268-278

**OP0058 CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONAL THERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STAR TRIAL**

van Vollenhoven, R. F., Rudin, A., Hetland, M. L., Heiberg, M. S., Nordström, D., Nurmohamed, M., Gudbjornsson, B., Midtbøll Ørnbjerg, L., Bøyesen, P., Olsen, I., Lend, K., Uhlig, T., Sokka-isler, T., Gröndal, G., Krabbe, S., Lindqvist, J., Gjørtsson, I., Glinatsi, D., Kapetanovic, M. C. & Aga, A.-B. & 16 flere, Faustini, F., Parmanne, P., Lorenzen, T., Cagnotto, G., Back, J., Vedder, D., Rannio, T., Grenholm, E., Lindegaard, H. M., Ljoså, M. K. A., Brodin, E., Söderbergh, A., Rizk, M., Hermansson, E., Uhrenholt, L. & Nord-Star Group, 1. jun. 2022, I: *Annals of the Rheumatic Diseases*. 81, suppl. 1, s. 38-40 OP0058.

**A retrospective cohort study of patients with eosinophilia referred to a tertiary centre**

Hougaard, M., Thomsen, G. N., Kristensen, T. K., Lindegaard, H. M., Davidsen, J. R., Hartmeyer, G. N., Kjeldsen, A. D., Martin-Iguacel, R., Maiborg, M., Assing, K., Andersen, C. L., Broesby-Olsen, S., Møller, M. B., Vestergaard, H. & Bjerrum, O. W., apr. 2022, I: *Danish Medical Journal*. 69, 4, A07210558.

**In vitro effect of biological and conventional disease-modifying antirheumatic drugs on fibrocyte differentiation in patients with rheumatoid arthritis and healthy controls**

Tenstad, H. B., Vinholt, P. J., Nielsen, C., Lindegaard, H. & Just, S. A., okt. 2021, I: *European Journal of Rheumatology*. 8, 4, s. 184-189

**Fibrocytes in early and long-standing rheumatoid arthritis: A 6-month trial with repeated synovial biopsy, imaging and lung function test**

Just, S. A., Nielsen, C., Werlinrud, J. C., Larsen, P. V., Hejbøl, E. K., Tenstad, H. B., Daa Schrøder, H., Barington, T., Torfing, T., Humby, F. & Lindegaard, H., 5. mar. 2021, I: *RMD Open*. 7, 1

**Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission**

Møller-Bisgaard, S., Georgiadis, S., Hørslev-Petersen, K., Ejbjerg, B., Hetland, M. L., Ørnbjerg, L. M., Glinatsi, D., Møller, J., Boesen, M., Stengaard-Pedersen, K., Madsen, O. R., Jensen, B., Villadsen, J. A., Hauge, E. M., Bennett, P., Hendricks, O., Asmussen, K., Kowalski, M., Lindegaard, H. & Bliddal, H. & 7 flere, Krogh, N. S., Ellingsen, T., Nielsen, A. H., Balding, L., Jurik, A. G., Thomsen, H. S. & Østergaard, M., 5. jan. 2021, I: *Rheumatology*. 60, 1, s. 380-391

**AB0414 The in vitro effect of biological and conventional disease modifying anti rheumatic drugs (DMARDs) on fibrocyte differentiation in rheumatoid arthritis patients and healthy controls**

Tenstad, H., Vinholt, P., Nielsen, C., Lindegaard, H. M. & Just, S. A., 1. nov. 2020.

**Complement activation in human autoimmune diseases and mouse models; employing a sandwich immunoassay specific for C3dg**

Troldborg, A., Halkjær, L., Pedersen, H., Hansen, A., Loft, A. G., Lindegaard, H., Stengaard-Pedersen, K., Graversen, J. H., Palarasah, Y. & Thiel, S., nov. 2020, I: *Journal of Immunological Methods*. 486, 112866.

**Rheumatoid arthritis treatment associated changes in circulating bone-turnover markers**

The CIMESTRA Study Group, okt. 2020, I: *Bone Reports*. 13, Suppl., s. 2-3 P010.

**TREAT-TO-TARGET STRATEGY OF >8.000 PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: DOES SMOKING AFFECT ACHIEVEMENT OF REMISSION ON METHOTREXATE AND TIME TO START OF FIRST BIOLOGIC? RESULTS FROM THE NATIONWIDE DANISH DANBIO REGISTRY**

Hendricks, O., Glinborg, B., Colic, A., Lindegaard, H. M., Ahmed, R., Loft, A. G., Kollerup, G. B., Andersen, M., Grydehøj, J., Raun, J., Thorgrimsen, T., Mortensen, K., Uhrenholt, L., Jensen, D., Ruge, I., Kalisz, M., Danebod, K., Lomborg, N., Krogh, N. S. & Hetland, M. L., 6. jun. 2020.

**Treat-to-target strategy of >8.000 patients with early rheumatoid arthritis: Does smoking affects achievement of remission on methotrexate and time to start of first biologic? Results from the nationwide Danish DANBIO registry**

Hendricks, O., Glinborg, B., Colic, A., Lindegaard, H. M., Ahmed, R., Loft, A. G., Kollerup, G. B., Andersen, M., Grydehøj, J., Raun, J., Thorgrimsen, T., Mortensen, K., Uhrenholt, L., Jensen, D., Ruge, I., Kalisz, M., Danebod, K., Lomborg, N., Krogh, N. S. & Hetland, M. L., 6. jun. 2020, I: *Annals of the Rheumatic Diseases*. 79, Suppl. 1, s. 997-999 3 s.

**CHARACTERISTICS OF PRIMARY SJOGREN'S SYNDROME INCLUDING ULTRASOUND FINDINGS OF THE SALIVARY GLANDS, ESSDAI AND ESSPRI**

Schmidt, N. S., Voss, A., Just, S. A. & Lindegaard, H. M., 1. jun. 2020, I: *Annals of the Rheumatic Diseases*. 79, Suppl. 1, s. 1059 1 s., SAT0233.

**THE IMPACT OF AN ULTRASOUND ATLAS FOR SCORING SALIVARY GLANDS IN PRIMARY SJOGREN'S SYNDROME: A RELIABILITY EXERCISE**

Schmidt, N. S., Fana, V., Lindegaard, H. M. & Terslev, L., 1. jun. 2020, I: *Annals of the Rheumatic Diseases*. 79, Suppl. 1, s. 193 1 s., OP0312.

**Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): An observational nationwide study applying linkage between DANBIO and national registries**

Glinborg, B., Georgiadis, S., Loft, A. G., Linauskas, A., Lindegaard, H., Hendricks, O., Jensen, D. V., Andersen, B. L., Danebod, K., Villumsen, A., Eng, G., Wiell, C., Manilo, N., Kristensen, S., Raun, J., Grydehøj, J., Chrysidis, S., Nørgaard, M., Mehnert, F. & Krogh, N. S. & 1 flere, Hetland, M. L., jun. 2020, I: *Annals of the Rheumatic Diseases*. 79, 6, s. 846-848

**Response to 'To switch or not to switch': The missing piece in the puzzle of biosimilar literature?' by Scherlinger et al**

Glinborg, B., Loft, A. G., Omerovic, E., Hendricks, O., Linauskas, A., Espesen, J., Danebod, K., Jensen, D. V., Nordin, H., Dalgaard, E. B., Chrysidis, S., Kristensen, S., Raun, J. L., Lindegaard, H., Manilo, N., Jakobsen, S. H., Hansen, I. M. J., Pedersen, D. D., Sørensen, I. J. & Andersen, L. S. & 4 flere, Grydehøj, J., Mehnert, F., Krogh, N. S. & Lund Hetland, M., apr. 2020, I: *Annals of the Rheumatic Diseases*. 79, 4, e37.

**Use and utility of serologic tests for rheumatoid arthritis in primary care**

Broch Tenstad, H., Nilsson, A. C., Dellgren, C., Lindegaard, H. M., Rubin, K. H. & Lillevang, S. T., 1. feb. 2020, I: *Danish Medical Journal*. 67, 2, 6 s., A05190318.

**Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB<sub>4</sub>: Possible fallout on non-medical switching' by Cantini and Benucci**

Glintborg, B., Loft, A. G., Omerovic, E., Hendricks, O., Linauskas, A., Espesen, J., Danebod, K., Jensen, D. V., Nordin, H., Dalgaard, E. B., Chrysidis, S., Kristensen, S., Raun, J. L., Lindegaard, H., Manilo, N., Jakobsen, S. H., Hansen, I. M. J., Dalsgaard Pedersen, D., Sørensen, I. J. & Andersen, L. S. & 4 flere, Grydehøj, J., Mehnert, F., Krogh, N. S. & Hetland, M. L., feb. 2020, I: *Annals of the Rheumatic Diseases*. 79, 2, 2 s., e14.

**Predictive values of anti-cyclic citrullinated peptide antibodies and rheumatoid factor in relation to serological aspects of the ACR/EULAR 2010 classification criteria for rheumatoid arthritis**

Tenstad, H. B., Nilsson, A. C., Dellgren, C. D., Lindegaard, H. M., Rubin, K. H. & Lillevang, S. T., jan. 2020, I: *Scandinavian Journal of Rheumatology*. 49, 1, s. 18-20

**Increased serum levels of microfibrillar-associated protein 4 (MFAP4) are not associated with clinical synovitis in rheumatoid arthritis but may reflect underlying cardiovascular comorbidity**

Issa, S. F., Lindegaard, H. M., Lorenzen, T., Junker, K., Christensen, A. F., Hørslev-Petersen, K., Holmskov, U., Sorensen, G. L. & Junker, P., 2020, I: *Clinical and Experimental Rheumatology*. 38, 1, s. 122-128

**Reumatologi**

Lindegaard, H. M., 2020, *Medicin*. Baslund, B., Kastrup, J., Soelberg Sørensen, P. & Feldt-Rasmussen, U. (red.). 3. udg. FADL's Forlag

**Magnetic Resonance Imaging in Patients in Clinical Remission: Tenosynovitis and Osteitis Are Independent Predictors of Radiographic and MRI Damage Progression**

Moller-Bisgaard, S., Hørslev-Petersen, K., Ejbjerg, B., Hetland, M. L., Ornbjerg, L. M., Glinatsi, D., Moller, J., Boesen, M., Stengaard-Pedersen, K., Madsen, O. R., Jensen, B., Villadsen, J. A., Hauge, E.-M., Bennett, P., Hendricks, O., Asmussen, K., Kowalski, M., Lindegaard, H., Bliddal, H. & Krogh, N. S. & 6 flere, Ellingsen, T., Nielsen, A., Balding, L., Jurik, A. G., Thomsen, H. & Ostergaard, M., okt. 2019, I: *Arthritis & Rheumatology*. 71, Suppl. 10, 1 s., 1173.

**Six-month prospective trial in early and long-standing rheumatoid arthritis: Evaluating disease activity in the wrist through sequential synovial histopathological analysis, RAMRIS magnetic resonance score and EULAR-OMERACT ultrasound score**

Just, S. A., Nielsen, C., Werlinrud, J. C., Larsen, P. V., Klinkby, C. S., Daa Schrøder, H., Humby, F., Torfing, T. & Lindegaard, H., 1. jul. 2019, I: *RMD Open*. 5, 2, 13 s., e000951.

**Comparing Disease Activity in the Wrist by Repeat Synovial Biopsies, Ramris Magnetic Resonance Score and Eular-Omeract Ultrasound Score: A 6-month Prospective Trial in Early and Longstanding Rheumatoid Arthritis**

Just, S. A., Nielsen, C., Werlinrud, J., Larsen, P. V., Klinkby, C. S., Schroder, H. D., Humby, F., Torfing, T. & Lindegaard, H. M., 1. jun. 2019, I: *Annals of the Rheumatic Diseases*. 78, Suppl. 2, s. 1017-1018 2 s.

**The In Vitro Effect of Biological and Conventional Disease Modifying Anti Rheumatic Drugs (DMARDS) on Fibrocyte Differentiation in Rheumatoid Arthritis Patients and Healthy Controls**

Tenstad, H., Vinholt, P. J., Nielsen, C., Lindegaard, H. M. & Just, S. A., 1. jun. 2019, I: *Annals of the Rheumatic Diseases*. 78, Suppl. 2, s. 1668-1669 2 s.

**Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis the IMAGINE-RA randomized clinical trial**

Møller-Bisgaard, S., Hørslev-Petersen, K., Ejbjerg, B., Hetland, M. L., Ørnbjerg, L. M., Glinatsi, D., Møller, J., Boesen, M., Christensen, R., Stengaard-Pedersen, K., Madsen, O. R., Jensen, B., Villadsen, J. A., Hauge, E. M., Bennett, P., Hendricks, O., Asmussen, K., Kowalski, M., Lindegaard, H. & Nielsen, S. M. & 8 flere, Bliddal, H., Krogh, N. S., Ellingsen, T., Nielsen, A. H., Balding, L., Jurik, A. G., Thomsen, H. S. & Østergaard, M., 5. feb. 2019, I: *JAMA - Journal of the American Medical Association*. 321, 5, s. 461-472

**To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry**

Glintborg, B., Loft, A. G., Omerovic, E., Hendricks, O., Linauskas, A., Espesen, J., Danebod, K., Jensen, D. V., Nordin, H., Dalgaard, E. B., Chrysidis, S., Kristensen, S., Raun, J. L., Lindegaard, H., Manilo, N., Jakobsen, S. H., Hansen, I. M. J., Dalsgaard Pedersen, D., Sørensen, I. J. & Andersen, L. S. & 4 flere, Grydehøj, J., Mehnert, F., Krogh, N. S. & Hetland, M.

L., 1. feb. 2019, I: Annals of the Rheumatic Diseases. 78, 2, s. 192-200

**Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial**

Brahe, C. H., Østergaard, M., Johansen, J. S., Defranoux, N., Wang, X., Bolce, R., Sasso, E., Ørnberg, L., Hørslev-Petersen, K., Stengaard-Pedersen, K., Junker, P., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T. & Ammitzbøll, C. & 4 flere, Jørgensen, A., Krintel, S., Raun, J. & Hetland, M., 2. jan. 2019, I: Scandinavian Journal of Rheumatology. 48, 1, s. 9-16

**Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis**

Hetland, M. L., Østergaard, M., Stengaard-Pedersen, K., Junker, P., Ejbjerg, B., Jacobsen, S., Ellingsen, T., Lindegaard, H., Pødenphant, J., Vestergaard, A., Jurik, A. G., Krogh, N. S., Hørslev-Petersen, K. & The CIMESTRA Study Group, jan. 2019, I: Scandinavian Journal of Rheumatology. 48, 1, s. 1-8

**Information is a key prerequisite for perceived relevance of patient reported outcome data (PRO data): A multicenter questionnaire study**

Kildemand, M., Lindegaard, H. M., Rothmann, M. J. & Nørgaard, B., 2019, I: Journal of Nursing Education and Practice. 9, 6, s. 107-112

**MAGNETIC RESONANCE IMAGING TENOSYNOVITIS AND OSTEITIS ARE INDEPENDENT PREDICTORS OF RADIOGRAPHIC AND MRI DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION**

Moller-Bisgaard, S., Hørslev-Petersen, K., Ejbjerg, B., Hetland, M. L., Ornbjerg, L., Glinatsi, D., Moller, J. M., Boesen, M., Stengaard-Pedersen, K., Madsen, O., Jensen, B., Villadsen, J., Hauge, E. M., Bennett, P., Hendricks, O., Asmussen, K., Kowalski, M., Lindegaard, H. M., Bliddal, H. & Krogh, N. S. & 6 flere, Ellingsen, T., Nielsen, A., Balding, L., Jurik, A. G., Thomsen, H. & Ostergaard, M., 2019, I: Annals of the Rheumatic Diseases. 78, Suppl. 2, OP0331.

**Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe**

Just, S. A., Humby, F., Lindegaard, H., Meric de Bellefon, L., Durez, P., Vieira-Sousa, E., Teixeira, R., Stoenoiu, M., Werlinrud, J., Rosmark, S., Larsen, P. V., Pratt, A., Choy, E., Gendi, N., Buch, M. H., Edwards, C. J., Taylor, P. C., McInnes, I. B., Fonseca, J. E. & Pitzalis, C. & 1 flere, Filer, A., okt. 2018, I: RMD Open. 4, 2, 10 s., e000799.

**Transmission of rheumatoid arthritis through blood transfusion: a retrospective cohort study**

Just, S. A., Rostgaard, K., Titlestad, K., Edgren, G., Erikstrup, C., Ullum, H., Pedersen, O. B., Nielsen, K. R., Askling, J., Lindegaard, H. & Hjalgrim, H., okt. 2018, I: Annals of the Rheumatic Diseases. 77, 10, s. 1536-1537

**An MRI Guided Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission Improved MRI Inflammation but Not Damage Progression - Results from the Imagine-RA Randomized Controlled Trial**

Moller-Bisgaard, S., Hørslev-Petersen, K., Ejbjerg, B. J., Glinatsi, D., Hetland, M. L., Ornbjerg, L., Moller, J. M., Boesen, M., Christensen, R., Stengaard-Pedersen, K., Madsen, O. R., Jensen, B., Villadsen, J. A., Hauge, E.-M., Bennett, P., Hendricks, O., Asmussen, K., Kowalski, M. R., Lindegaard, H. & Nielsen, S. M. & 8 flere, Bliddal, H., Krogh, N. S., Ellingsen, T., Nielsen, A., Balding, L., Jurik, A. G., Thomsen, H. S. & Ostergaard, M., 1. sep. 2018, I: Arthritis & Rheumatology. 70, Suppl. 9, 1 s., 867.

**Is 14.3.3 eta a Predictor of Development of Rheumatoid Arthritis in Patients with Early Undifferentiated Arthritis?**

Carlsen, K. M., Schmidt, N., Duer, A., Hørslev-Petersen, K., Brahe, C. H., Hetland, M. L., Biln, N. K., Zaharik, M. L., Ejbjerg, B. J., Bak, L., Hansen, M. S., Johansen, J. S., Lindegaard, H. M., Moller, J. M. & Ostergaard, M., 1. sep. 2018, I: Arthritis & Rheumatology. 70, Suppl. 9, 1 s.

**Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care**

Glintborg, B., Kringelbach, T., Bolstad, N., Warren, D. J., Eng, G., Sørensen, I. J., Loft, A. G., Hendricks, O., Hansen, I., Linauskas, A., Nordin, H., Kristensen, S., Lindegaard, H., Jensen, D. V., Goll, G. L., Høgdall, E., Gehin, J., Enevold, C., Nielsen, C. H. & Krogh, N. S. & 2 flere, Johansen, J. S. & Hetland, M. L., sep. 2018, I: Scandinavian Journal of Rheumatology. 47, 5, s. 418-421

**Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials**

Brahe, C. H., Dehlendorff, C., Østergaard, M., Johansen, J. S., Ørnbjerg, L. M., Hørslev-Petersen, K., Stengaard-Pedersen, K., Junker, P., Ellingsen, T., Lindegaard, H., Hansen, I., Lottenburger, T., Jacobsen, S., Jurik, A. G. & Hetland, M. L., 4. jul. 2018, I: *Scandinavian Journal of Rheumatology*. 47, 4, s. 259-269

**One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the DANBIO registry**

Glintborg, B., Sørensen, I. J., Omerovic, E., Mehnert, F., Manilo, N., Danebod, K., Dorte Vendelbo, J., Nordin, H., Loft, A. G., Hendricks, O., Chrysidis, S., Andersen, B. L., Lillelund Raun, J., Lindegaard, H. M., Espesen, J., Jakobsn, S. H., Jensen Hansen, I. M., Dalsgaard, E. B., Krogh, N. & Hetland, M. L., 14. jun. 2018.

**One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study**

Glintborg, B., Sørensen, I. J., Omerovic, E., Mehnert, F., Manilo, N., Danebod, K., Jensen, D. V., Nordin, H., Loft, A. G., Hendricks, O., Chrysidis, S., Andersen, B. L., Lillelund Raun, J., Lindegaard, H. M., Espesen, J., Højmark Jakobsen, S., Jensen Hansen, I. M., Dalsgaard, E. B., Pedersen, D. D. & Kristensen, S. & 7 flere, Linauskas, A., Andersen, L. S., Grydehøj, J., Krogh, N. S., Hetland, M. L., All Departments of Rheumatology in Denmark & The Danbio Registry, jun. 2018, I: *Annals of the Rheumatic Diseases*. 77, Suppl. 2, s. 595-596 2 s., FRI0103.

**Patient reported outcomes and safety in patients undergoing synovial biopsy: comparison of arthroscopic, ultrasound-guided portal-forceps and ultrasound-guided needle biopsy techniques, in five centres across europe.**

Just, S. A., Humby, F., Lindegaard, H., de Bellefon, L. M., Durez, P., Vieira-Sousa, E., Teixeira, R., Stoenoiu, M., Werlinrud, J., Rosmark, S., Larsen, P. V., Pitzalis, C. & Filer, A., jun. 2018, I: *Annals of the Rheumatic Diseases*. 77, Suppl. 2, s. 187 1 s.

**The use of synthetic peptides for detection of anti-citrullinated protein antibodies in rheumatoid arthritis**

Trier, N. H., Holm, B. E., Heiden, J., Slot, O., Loch, H., Jensen, B., Lindegaard, H., Svendsen, A., Nielsen, C. T., Jacobsen, S., Theander, E. & Houen, G., mar. 2018, I: *Journal of Immunological Methods*. 454, s. 6-14

**Antibodies to a strain-specific citrullinated Epstein-Barr virus peptide diagnoses rheumatoid arthritis**

Trier, N. H., Holm, B. E., Heiden, J., Slot, O., Loch, H., Lindegaard, H., Svendsen, A., Nielsen, C. T., Jacobsen, S., Theander, E. & Houen, G., 27. feb. 2018, I: *Scientific Reports*. 8, 11 s., 3684.

**Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study**

Lindegaard, H. M. (Medlem af forfattergruppering), Bjørning-Poulsen, M. (Medlem af forfattergruppering), Ellingsen, T. J. (Medlem af forfattergruppering), Munk, H. L. (Medlem af forfattergruppering) & Biomarker Protocol Study Group, 1. feb. 2018, I: *BMJ Open*. 8, 2, s. e019325 e019325.

**Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers**

Cordtz, R. L., Zobbe, K., Højgaard, P., Kristensen, L. E., Overgaard, S., Odgaard, A., Lindegaard, H. & Dreyer, L., feb. 2018, I: *Annals of the Rheumatic Diseases*. 77, 2, s. 281-288

**The Value of Adding MRI to a Clinical Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission. Clinical and Radiographic Outcomes from the Imagine-RA Randomized Controlled Trial.**

Møller-Bisgaard, S., Hørslev-Petersen, K., Ejbjerg, B. J., Lund Hetland, M., Glinatsi, D., Ørnbjerg, L. M., Møller, J. M., Boesen, M., Christensen, R., Stengaard-Pedersen, K., Madsen, O. R., Jensen, B., Villadsen, J. A., Hauge, E. M., Bennett, P., Hendricks, O., Asmussen, K., Kowalski, M. R., Lindegaard, H. M. & Mai Nielsen, S. & 8 flere, Bliddal, H., Krogh, N. S., Ellingsen, T. J., Nielsen, A., Balding, L., Jurik, A. G., Thomsen, H. S. & Østergaard, M., 2018.

**Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial**

Nguyen, M. T. T., Lindegaard, H., Hendricks, O., Jørgensen, C. S., Kantsø, B. & Friis-Møller, N., 1. dec. 2017, I: *The Journal of Rheumatology*. 44, 12, s. 1794-1803

**Galectin-3 is Persistently Increased in Early Rheumatoid Arthritis (RA) and Associates with Anti-CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity**

Issa, S. F., Christensen, A. F., Lindegaard, H. M., Hetland, M. L., Hørslev-Petersen, K., Stengaard-Pedersen, K., Ejbjerg, B. J., Lottenburger, T., Ellingsen, T., Pedersen, J. K., Junker, K., Svendsen, A., Tarp, U., Østergaard, M. & Junker, P., dec. 2017, I: *Scandinavian Journal of Immunology*. 86, 6, s. 471–478

**One-year clinical outcomes in 1621 patients with inflammatory arthritis who switched from originator to biosimilar etanercept. An observational study from the Danish DANBIO registry**

Hendricks, O., Glinborg, B., Omerovic, E., Danebod, K., Dorte Vendelbo, J., Nordin, H., Loft, A. G., Chrysidis, S., Lillelund Raun, J., Lindegaard, H. M., Espesen, J., Jakobsen, S., Jensen Hansen, I. M., Grydehøj, J., Dalgaard, E. B., Dalsgaard Pedersen, D., Manilo, N., Andersen, L. S., Kristensen, S. & Linauskas, A. & 2 flere, Steen Krogh, N. & Hetland, M. L., 7. nov. 2017.

**National Behandlingsvejledning (NBV): Reumatoid Arthritis**

Schlemmer, A., Uhrenholt, L., Danielsen, M. A., Ellingsen, T. J., Hauge, E., Holland-Fischer, M., Keller, K., Lindegaard, H., Lorenzen, T., Masic, D., Rødgaard, A. & Terslev, L., 8. okt. 2017, 27 s.

**One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept: an Observational Study from the Danish Danbio Registry**

Glinborg, B., Omerovic, E., Danebod, K., Jensen, D. V., Nordin, H., Loft, A. G., Chrysidis, S., Raun, J. L., Hendricks, O., Lindegaard, H., Espesen, J., Jakobsen, S., Hansen, I. M. J., Grydehøj, J., Dalgaard, E., Pedersen, D. D., Manilo, N., Andersen, L. S., Kristensen, S. & Linauskas, A. & 2 flere, Krogh, N. S. & Hetland, M. L., okt. 2017, I: *Arthritis & Rheumatology*. 69, Suppl. 10, 1550.

**One-year clinical outcomes in 1623 patients with inflammatory arthritis who switched from originator to biosimilar Etanercept - an observational study from the Danish Danbio Registry**

Glinborg, B., Omerovic, E., Danebod, K., Dorte Vendelbo, J., Nordin, H., Loft, A. G., Chrysidis, S., Lillelund Raun, J., Hendricks, O., Lindegaard, H. M., Espesen, J., Jakobsen, S., Jensen Hansen, I. M., Grydehøj, J., Dalgaard, E. B., Dalsgaard Pedersen, D., Manilo, N., Andersen, L. S., Kristensen, S. & Linauskas, A. & 2 flere, Steen Krogh, N. & Hetland, M. L., okt. 2017, I: *Arthritis & Rheumatology*. 69, Suppl. 10, 1 s., 1550.

**Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)**

Møller-Bisgaard, S., Ejbjerg, B. J., Eshed, I., Hørslev-Petersen, K., Hetland, M. L., Jurik, A. G., Thomsen, H., Torfing, T., Stengaard-Pedersen, K., Junker, P., Krogh, N. S., Lottenburger, T., Ellingsen, T., Andersen, L. S., Skjødt, H., Svendsen, A. J., Tarp, U., Hansen, I. T., Pødenphant, J. & Pedersen, J. K. & 5 flere, Lindegaard, H., Hanson, L. G., Vestergaard, A., Glinatsi, D. & Østergaard, M., 3. sep. 2017, I: *Scandinavian Journal of Rheumatology*. 46, 5, s. 335-345

**A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry**

Glinborg, B., Sørensen, I. J., Loft, A. G., Lindegaard, H., Linauskas, A., Hendricks, O., Hansen, I. M. J., Jensen, D. V., Manilo, N., Espesen, J., Klarlund, M., Grydehøj, J., Dieperink, S. S., Kristensen, S., Olsen, J. S., Nordin, H., Chrysidis, S., Dalsgaard Pedersen, D., Sørensen, M. V. & Andersen, L. S. & 5 flere, Grøn, K. L., Krogh, N. S., Pedersen, L., Hetland, M. L. & All Departments of Rheumatology in Denmark, aug. 2017, I: *Annals of the Rheumatic Diseases*. 76, 8, s. 1426-1431

**Fibrocyte measurement in peripheral blood correlates with number of cultured mature fibrocytes in vitro and is a potential biomarker for interstitial lung disease in Rheumatoid Arthritis**

Just, S. A., Lindegaard, H., Hejbøl, E. K., Davidsen, J. R., Bjerring, N., Hansen, S. W. K., Schrøder, H. D., Hansen, I. M. J., Barington, T. & Nielsen, C., 18. jul. 2017, I: *Respiratory Research*. 18, 13 s., 141.

**Safety, feasibility and tolerability of performing consecutive minimal invasive ultrasound-guided synovial biopsy procedures on the same wrist in a prospective rheumatoid arthritis study**

Just, S. A., Nielsen, C., Hejbøl, E. K., Schroder, H. D., Hansen, I. M. J., Barington, T. & Lindegaard, H. M., 17. jun. 2017, I: *Annals of the Rheumatic Diseases*. 76, 2, 1 s., SAT0660.



**Clinical outcomes of a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months' follow-up. Results from the DANBIO registry.**

Glintborg, B., Sørensen, I. J., Loft, A. G., Espesen, J., Jensen, D. V., Danebod, K., Dieperink, S. S., Hendricks, O., Jensen Hansen, I. M., Linauskas, A., Kristensen, S., Andersen, L. S., Hossein, M., Nordin, H., Andersen, B. L., Chrysidis, S., Raun, J. L., Lindegaard, H. M., Manilo, N. & Grydehøj, J. & 4 flere, Dalgaard, E. B., Dalsgaard Pedersen, D., Niels Steen, K. & Hetland, M. L., 16. jun. 2017, I: *Annals of the Rheumatic Diseases*. 76, Suppl. 2

**Wrist inflammation as assessed by magnetic resonance imaging is associated with patient-reported physical impairment, global disease activity and pain in early rheumatoid arthritis: Long-term results from two randomized controlled trials**

Glinatsi, D., Baker, J. F., Hetland, M. L., Hørslev-Petersen, K., Ejbjerg, B. J., Stengaard-Pedersen, K., Junker, P., Ellingsen, T. J., Lindegaard, H. M., Hansen, I., Lottenburger, T., Møller, J. M., Ornbjerg, L. M., Vestergaard, A., Jurik, A. G., Thomsen, H. S., Torfing, T., Møller-Bisgaard, S., Axelsen, M. B. & Østergaard, M., 16. jun. 2017. 1 s.

**Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets**

Issa, S. F., Duer-Jensen, A., Østergaard, M., Hørslev-Petersen, K., Hetland, M. L., Hansen, M. S., Junker, K., Lindegaard, H. M., Møller, J. M. & Junker, P., 26. apr. 2017, I: *Arthritis Research & Therapy*. 19, 10 s., 80.

**Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab: a substudy of the optimized treatment algorithm in early RA (OPERA) trial**

Ørnbjerg, L. M., Østergaard, M., Jensen, T., Hørslev-Petersen, K., Stengaard-Pedersen, K., Junker, P., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B., Raun, J., Hetland, M. L. & OPERA Study Group & 11 flere, Slot, O., Nielsen, L. K., Skjødt, H., Majgaard, O., Lorenzen, T., Horn, H. C., Kowalski, M., Johansen, I. L., Pedersen, P. M., Manilo, N. & Bliddal, H., 1. apr. 2017, I: *Clinical Rheumatology*. 36, 4, s. 781–789

**11 years' follow-up of a danish 2-year treat-to-target randomized controlled trial in patients with early rheumatoid arthritis: baseline predictors of functional and radiographic outcomes**

Hetland, M. L., Stengaard-Pedersen, K., Junker, P., Lindegaard, H. M., Ellingsen, T. J., Pødenphant, J., Skjødt, H., Vestergaard, A., Ejbjerg, B. J., Jacobsen, S., Steen Krogh, N., Østergaard, M. & Hørslev-Petersen, K., 2017, I: *Annals of the Rheumatic Diseases*. 76, suppl. 2, 1 s., SAT0045.

**Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax\_RA)**

Nguyen, M., Lindegaard, H., Hendricks, O. & Friis-Møller, N., 2017, I: *Scandinavian Journal of Rheumatology*. 46, 6, s. 446-453

**Health anxiety by proxy in women with severe health anxiety: A case control study**

Thorgaard, M. V., Frostholm, L., Walker, L., Jensen, J. S., Morina, B., Lindegaard, H., Salomonsen, L. & Rask, C. U., 2017, I: *Journal of Anxiety Disorders*. 52, s. 8-14

**Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials**

Glinatsi, D., Baker, J. F., Hetland, M. L., Hørslev-Petersen, K., Ejbjerg, B. J., Stengaard-Pedersen, K., Junker, P., Ellingsen, T., Lindegaard, H. M., Hansen, I., Lottenburger, T., Møller, J. M., Ørnbjerg, L. M., Vestergaard, A., Jurik, A. G., Thomsen, H. S., Torfing, T., Møller-Bisgaard, S., Axelsen, M. B. & Østergaard, M., 2017, I: *Annals of the Rheumatic Diseases*. 76, 10, s. 1707-1715

**Obtaining synovial biopsies from the wrist in patients with newly diagnosed untreated and longstanding rheumatoid arthritis followed by intramuscular glucocorticoid and methotrexate initiation is safe and the glucocorticoid treatment significantly reduces disease activity.**

Just, S. A., Nielsen, C., Hejbøl, E. K., Schrøder, H. D., Jensen Hansen, I. M., Barington, T. & Lindegaard, H. M., 2017.

**Risk of revision, prosthetic joint infection and death following total hip or knee arthroplasty in patients with rheumatoid arthritis – a nationwide cohort study from denmark**

Cordtz, R. L., Kristensen, L. E., Overgaard, S., Odgaard, A., Lindegaard, H. & Dreyer, L., 2017, I: *Annals of the Rheumatic Diseases*. 76, 1 s., 226.

**Safety, feasibility and tolerability of performing consecutive minimal invasive ultrasound-guided synovial biopsy procedures on the same wrist in a prospective rheumatoid arthritis study**

Just, S. A., Nielsen, C., Hejbøl, E. K., Schrøder, H., Jensen Hansen, I. M., Barington, T. & Lindegaard, H. M., 2017.

**Safety, feasibility and tolerability of performing consecutive minimal invasive ultrasound-guided synovial biopsy procedures on the same wrist in a prospective Rheumatoid Arthritis study**

Just, S. A., Nielsen, C., Hejbøl, E. K., Schrøder, H., Jensen Hansen, I. M., Barington, T. & Lindegaard, H. M., 2017.

**The role of ultrasound in diagnosing rheumatoid arthritis, what do we know? An updated review**

Rask Lage-Hansen, P., Lindegaard, H. M., Chrysidis, S. & Terslev, L., 2017, I: *Rheumatology International*. 37, 2, s. 179-187

**Wrist inflammation as assessed by magnetic resonance imaging is associated with patient-reported physical impairment, global disease activity and pain in early rheumatoid arthritis: Long-term results from two randomized controlled trials**

Glinatsi, D., Baker, J. F., Hetland, M. L., Hørslev-Petersen, K., Ejbjerg, B. J., Stengaard-Pedersen, K., Junker, P., Ellingsen, T. J., Lindegaard, H. M., Hansen, I., Lottenburger, T., Møller, J. M., Ornbjerg, L. M., Vestergaard, A., Jurik, A. G., Thomsen, H. S., Torfing, T., Møller-Bisgaard, S., Axelsen, M. B. & Østergaard, M., 2017, I: *Annals of the Rheumatic Diseases*. 76, Suppl. 2, s. 732 1 s., FRI0641.

**Physical characteristics of a citrullinated pro-flaggrin epitope recognized by anti-citrullinated protein antibodies in rheumatoid arthritis sera**

Trier, N. H., Holm, B. E., Slot, O., Loch, H., Lindegaard, H., Svendsen, A. J. & Houen, G., dec. 2016, I: *PLOS ONE*. 11, 12, 16 s., e0168542.

**Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab**

Brahe, C. H., Østergaard, M., Johansen, J. S., Defranoux, N. A., Wang, X., Bolce, R. J., Sasso, E. H., Hørslev-Petersen, K., Stengaard-Pedersen, K., Ornbjerg, L. M., Junker, P., Ellingsen, T. J., Ahlquist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I. T., Lottenburger, T. & Ammitzbøll, C. G. & 4 flere, Jørgensen, A., Krintel, S. B., Lillelund Raun, J. & Hetland, M. L., 15. nov. 2016.

**Hand Bone Loss in Early Rheumatoid Arthritis Is Independent of Adalimumab Treatment - Results from a Randomized Controlled Clinical Trial.**

Ornbjerg, L. M., Østergaard, M., Jensen, T. D., Hørslev-Petersen, K., Stengaard-Pedersen, K., Junker, P., Ellingsen, T. J., Ahlquist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I. T., Lottenburger, T., Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B., Lillelund Raun, J. & Hetland, M. L., 14. nov. 2016.

**Magnetic Resonance Imaging (MRI) Joint Space Narrowing Is an Independent Predictor of Radiographic and MRI Damage Progression in Patients with Early Rheumatoid Arthritis**

Møller-Bisgaard, S., Ejbjerg, B. J., Eshed, I., Hørslev-Petersen, K., Hetland, M. L., Jurik, A. G., Thomsen, H. S., Torfing, T., Stengaard-Pedersen, K., Junker, P., Steen Krogh, N., Lottenburger, T., Ellingsen, T. J., Smedegaard-Andersen, L., skjød, H., Svendsen, A. J., Tarp, U., Hansen, I. T., Pødenphant, J. & Kristian Pedersen, J. & 4 flere, Lindegaard, H. M., Vestergaard, A., Glinatsi, D. & Østergaard, M., 13. nov. 2016.

**10+ Years' Follow-up of a Danish 2-Year Treat-to-Target RCT in Patients with Early Rheumatoid Arthritis: Baseline Predictors of Functional and Radiographic Outcomes**

Hetland, M. L., Stengaard-Pedersen, K., Junker, P., Lindegaard, H. M., Ellingsen, T. J., Pødenphant, J., skjød, H., Vestergaard, A., Ejbjerg, B. J., Jacobsen, S., Steen Krogh, N., Østergaard, M. & Hørslev-Petersen, K., okt. 2016, I: *Arthritis & Rheumatology*. 68, S 10, 3 s., 3210.

**Circulating CD45+CD34+CD11+ cells are immature fibrocytes and the level correlates with the number of mononuclear cells that in vitro differentiate to mature fibrocytes: A potential new marker for intestinal lung disease in rheumatoid arthritis**

Just, S. A., Nielsen, C., Rømhild Davidsen, J., Bjerring, N., Hejbøl, E. K., Hansen, S., Schrøder, H. D., Jensen Hansen, I. M. & Lindegaard, H. M., 15. jul. 2016, I: *Annals of the Rheumatic Diseases*. 75, Suppl. 2, s. 681 1 s., SAT0049.

**HAND BONE LOSS IN EARLY RHEUMATOID ARTHRITIS IS INDEPENDENT OF ADALIMUMAB TREATMENT. A SUBSTUDY OF THE OPTIMIZED TREATMENT ALGORITHM IN EARLY RA (OPERA) TRIAL**

Ørnbjerg, L., Østergaard, M., Jensen, T., Hørslev-Petersen, K., Stengaard-Pedersen, K., Junker, P., Ellingsen, T. J., Ahlquist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B., Lillelund Raun, J. & Hetland, M., 10. jun. 2016.

**HAND BONE LOSS IN EARLY RHEUMATOID ARTHRITIS IS INDEPENDENT OF ADALIMUMAB TREATMENT. A SUBSTUDY OF THE OPTIMIZED TREATMENT ALGORITHM IN EARLY RA (OPERA) TRIAL**

Ørnbjerg, L. M., Østergaard, M., Jensen, T., Hørslev-Petersen, K., Stengaard-Pedersen, K., Junker, P., Ellingsen, T. J., Ahlquist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Ammitzbøll, C. G., Jørgensen, A., Krintel, S., Lillelund Raun, J. & Hetland, M., 10. jun. 2016.

**MAGNETIC RESONANCE IMAGING JOINT SPACE NARROWING IS AN INDEPENDENT PREDICTOR OF RADIOGRAPHIC AND MRI DAMAGE PROGRESSION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS**

Møller-Bisgaard, S., Ejbjerg, B. J., Eshed, I., Hørslev-Petersen, K., Lund Hetland, M., Jurik, A. G., Thomsen, H., Torfing, T., Stengaard-Pedersen, K., Junker, P., Steen Krogh, N., Lottenburger, T., Ellingsen, T. J., Smedegaard-Andersen, L., skjødt, H., Svendsen, A. J., Tarp, U., Hansen, I., Pødenphant, J. & Lindegaard, H. M. & 2 flere, Vestergaard, A. & Glinatsi, D., 10. jun. 2016.

**MAGNETIC RESONANCE IMAGING JOINT SPACE NARROWING IS AN INDEPENDENT PREDICTOR OF RADIOGRAPHIC AND MRI DAMAGE PROGRESSION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS**

Møller-Bisgaard, S., Ejbjerg, B. J., Eshed, I., Hørslev-Petersen, K., Hetland, M., Jurik, A. G., Thomsen, H., Torfing, T., Stengaard-Pedersen, K., Junker, P., Steen Krogh, N., Lottenburger, T., Ellingsen, T. J., Smedegaard-Andersen, L., skjødt, H., Svendsen, A. J., Tarp, U., Hansen, I., Pødenphant, J. & Pedersen, J. K. & 4 flere, Lindegaard, H. M., Vestergaard, A., Glinatsi, D. & Østergaard, M., jun. 2016. 1 s.

**Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis**

Krintel, S. B., Dehlendorff, C., Hetland, M. L., Hørslev-Petersen, K., Andersen, K. K., Junker, P., Pødenphant, J., Ellingsen, T., Ahlquist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Horn, H. C., Jørgensen, A., Raun, J., Ammitzbøll, C. G., Østergaard, M. & Stengaard-Pedersen, K. & 1 flere, Johansen, J. S., apr. 2016, I: The Pharmacogenomics Journal. 16, 2, s. 141–146 6 s.

**Establishment of age- and sex-adjusted reference data for hand bone mass and investigation of hand bone loss in patients with rheumatoid arthritis treated in clinical practice: an observational study from the DANBIO registry and the Copenhagen Osteoarthritis Study**

Ørnbjerg, L. M., Østergaard, M., Jensen, T., Hyldstrup, L., Bach-Mortensen, P., Bøyesen, P., Thormann, A., Tarp, U., Bøhme, W. P., Lindegaard, H., Poulsen, U. E., Schlemmer, A., Graudal, N., Rødgaard, A., Espesen, J., Kollerup, G. B., Glinborg, B., Madsen, O. R., Jensen, D. V. & Hetland, M. L., 24. feb. 2016, I: Arthritis Research & Therapy. 18, 12 s., 53.

**Application of synthetic peptides for detection of anti-citrullinated peptide antibodies**

Trier, N. H., Holm, B. E., Slot, O., Loch, H., Lindegaard, H., Svendsen, A. J., Nielsen, C. T., Jacobsen, S., Theander, E. & Houen, G., feb. 2016, I: Peptides. 76, s. 87-95

**Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious**

Lindegaard, H. M., Johansen, P., Grøndal, G., Jensen, E. C., Juul, L., Schlemmer, A. M., Agular, B. & Jensen Hansen, I. M., 4. jan. 2016, I: Scandinavian Journal of Rheumatology. 45, 4, s. 262-266 5 s.

**Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci**

Nexø, B. A., Villesen, P., Nissen, K. K., Lindegaard, H. M., Rossing, P., Petersen, T., Tarnow, L., Hansen, B., Lorenzen, T., Hørslev-Petersen, K., Jensen, S. B., Bahrami, S., Lajer, M., Schmidt, K. L. M., Parving, H.-H., Junker, P. & Laska, M. J., 2016, I: Immunologic Research. 64, 1, s. 55-63

**Circulating CD45+ CD34+ CD11b+ cells are immature fibrocytes and the level correlates with the number of mononuclear cells that in vitro differentiate to mature fibrocytes: a potential new marker for interstitial lung disease in rheumatoid arthritis**

Just, S. A., Nielsen, C., Rømhild Davidsen, J., Bjerring, N., Hejbøl, E. K., Hansen, S., Schrøder, H. D., Jensen Hansen, I. M., Barington, T. & Lindegaard, H. M., 2016.

**Circulating CD45+ CD34+ CD11b+ cells are immature fibrocytes and the level correlates with the number of mononuclear cells that in vitro differentiate to mature fibrocytes: A potential new marker for interstitial lung disease in Rheumatoid Arthritis**

Just, S. A., Nielsen, C., Rømhild Davidsen, J., Bjerring, N., Hejbøl, E. K., Hansen, S., Schrøder, H. D., Jensen Hansen, I. M., Barington, T. & Lindegaard, H. M., 2016.

**Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)**

Hørslev-Petersen, K., Hetland, M. L., Ørnbjerg, L. M., Junker, P., Pødenphant, J., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B., Raun, J., Johansen, J. S., Østergaard, M. & Stengaard-Pedersen, K. & 1 flere, OPERA Study Group, 2016, I: *Annals of the Rheumatic Diseases*. 75, 9, s. 1645-1653

**Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study**

Larsen, K. S., Pottegård, A., Lindegaard, H. M. & Hallas, J., 2016, I: *The American Journal of Medicine*. 129, 3, s. 299-306.e2

**Factors Associated with influenza and pneumococcal vaccine uptake among Danish rheumatoid arthritis patients invited to participate in a pneumococcal vaccine trial (Immunovax\_RA)**

Nguyen, A. M., Lindegaard, H. M., Hendricks, O. & Friis-Møller, N., 2016.

**Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study**

Søltøft Larsen, K., Pottegård, A., Lindegaard, H. M. & Hallas, J., 2016, I: *PLOS ONE*. 11, 1, s. 1-13 e0146172.

**Inflammatoriske ledsygdomme**

Lindegaard, H. M. & Deleuran, B., 2016, *Medicin*. Baslund, B., Feldt-Rasmussen, U., Kastrup, J. & Soelberg Sørensen, P. (red.). 2. udg. København: FADL's Forlag, s. 820-836

**Risk of Rheumatoid Arthritis after Transfusion of Blood from Donors Later Diagnosed with Rheumatoid Arthritis: A Retrospective Cohort Study**

Just, S. A., Titlestad, K., Edgren, G., Rostgaard, K., Askling, J., Lindegaard, H. & Hjalgrim, H., 2016, I: *Arthritis & Rheumatology*. 68, Suppl. 10, 988.

**Effect of a Non Biologic Treat-to-Target Strategy on MRI-Determined Inflammatory and Destructive Changes in Early Rheumatoid Arthritis – Results from a 2-Year Investigator-Initiated Double-Blind Randomized Controlled Clinical Trial**

Møller-Bisgaard, S., Ejbjerg, B. J., Eshed, I., Hørslev-Petersen, K., Hetland, M. L., Jurik, A. G., Vallø, J., Thomsen, H., Torfing, T., Stengaard-Pedersen, K., Junker, P., Steen Krogh, N., Lottenburger, T., Ellingsen, T., Smedegaard-Andersen, L., Hansen, I. T., skjødt, H., Svendsen, A. J., Tarp, U. & Pødenphant, J. & 3 flere, Pedersen, J. K., Lindegaard, H. M. & Østergaard, M., 9. nov. 2015.

**Effect of a Non Biologic Treat-to-Target Strategy on MRI-Determined Inflammatory and Destructive Changes in Early Rheumatoid Arthritis – Results from a 2-Year Investigator-Initiated Double-Blind Randomized Controlled Clinical Trial**

Møller-Bisgaard, S., Ejbjerg, B. J., Eshed, I., Hørslev-Petersen, K., Hetland, M. L., Jurik, A. G., Vallø, J., Thomsen, H., Torfing, T., Stengaard-Pedersen, K., Junker, P., Steen Krogh, N., Lottenburger, T., Ellingsen, T., Smedegaard-Andersen, L., Hansen, I., skjødt, H., Svendsen, A. J., Tarp, U. & Pødenphant, J. & 3 flere, Pedersen, J. K., Lindegaard, H. M. & Østergaard, M., 9. nov. 2015.

**MRI Erosions in Undifferentiated Arthritis. Different Associations with the Collagen IIA N-Terminal Propeptide (PIIANP) and Galectin-3 in Pre-RA and Other Arthritides**

Issa, S. F., Duer-Jensen, A., Østergaard, M., Lindegaard, H. M., Hørslev-Petersen, K., Hetland, M. L., Møller, J. M., Christensen, A. F. & Junker, P., 9. nov. 2015.

**Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study**

Larsen, K. S., Pottegård, A., Lindegaard, H. M. & Hallas, J., 29. okt. 2015, I: *Arthritis Research & Therapy*. 17, 1, 7 s., 304.

**Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry**

Jørgensen, T. S., Kristensen, L. E., Christensen, R., Bliddal, H., Lorenzen, T., Hansen, M. S., Østergaard, M., Jensen, J., Zanjani, L., Laursen, T., Butt, S., Dam, M. Y., Lindegaard, H. M., Espesen, J., Hendricks, O., Kumar, P., Kincses, A., Larsen, L. H., Andersen, M. & Næser, E. K. & 10 flere, Jensen, D. V., Grydehøj, J., Unger, B., Dufour, N., Sørensen, V., Vildhøj, S., Jensen Hansen, I. M., Raun, J., Krogh, N. S. & Lund Hetland, M., 13. jul. 2015, I: *Rheumatology*. 54, 12, s. 2156-2165

**Within-day variation and influence of physical exercise on circulating Galectin-3 in patients with rheumatoid arthritis and healthy individuals**

Issa, S. F., Christensen, A. F., Lottenburger, T., Junker, K., Lindegaard, H., Hørslev-Petersen, K. & Junker, P., jul. 2015, I: *Scandinavian Journal of Immunology*. 82, 1, s. 70-75

**Effect of Methotrexate and Intra-Articular Betamethasone with or Without Additional Cyclosporine on Magnetic Resonance Imaging (MRI)-Determined Inflammatory and Destructive Changes in Very Early Rheumatoid Arthritis – Results from a 24-Months' Randomised Double Blind Placebo Controlled Trial**

Møller-Bisgaard, S., Ejbjerg, B. J., Eshed, I., Hørslev-Petersen, K., Jurik, A. G., Vallø, J., Thomsen, H., Torfing, T., Stengaard-Pedersen, K., Hetland, M. L., Junker, P., Steen Krogh, N., Lottenburger, T., Ellingsen, T., Smedegaard-Andersen, L., Hansen, I., Skjødt, H., Svendsen, A. J., Tarp, U. & Pødenphant, J. & 2 flere, Lindegaard, H. M. & Østergaard, M., 12. jun. 2015.

**Effect of Methotrexate and Intra-Articular Betamethasone with or Without Additional Cyclosporine on Magnetic Resonance Imaging (MRI)-Determined Inflammatory and Destructive Changes in Very Early Rheumatoid Arthritis – Results from a 24-Months' Randomised Double Blind Placebo Controlled Trial**

Møller-Bisgaard, S., Ejbjerg, B. J., Eshed, I., Hørslev-Petersen, K., Jurik, A. G., Vallø, J., Thomsen, H., Torfing, T., Stengaard-Pedersen, K., Hetland, M. L., Junker, P., Steen Krogh, N., Lottenburger, T., Ellingsen, T., Smedegaard-Andersen, L., Hansen, I., Skjødt, H., Svendsen, A. J., Tarp, U. & Pødenphant, J. & 3 flere, Pedersen, J. K., Lindegaard, H. M. & Østergaard, M., 10. jun. 2015, I: *Annals of the Rheumatic Diseases*. 74, 2. Supplement, s. 648 1 s.

**Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study**

Eng, G. P., Bendtzen, K., Bliddal, H., Stoltenberg, M., Szkudlarek, M., Fana, V., Lindegaard, H. M., Omerovic, E., Højgaard, P., Jensen, E. K. & Bouchelouche, P. N., 2015, I: *Arthritis*. 2015, 7 s., 784825.

**A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial**

Axelsen, M. B., Eshed, I., Hørslev-Petersen, K., Stengaard-Pedersen, K., Hetland, M. L., Møller, J. R., Junker, P., Pødenphant, J., Schlemmer, A., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Dam, M. Y., Hansen, I. T., Horn, H. C., Ammitzbøll, C. G., Jørgensen, A. J., Krintel, S. B. & Raun, J. & 4 flere, Krogh, N. S., Johansen, J. S., Østergaard, M. & OPERA Study Group, 2015, I: *Annals of the Rheumatic Diseases*. 74, 5, s. 867-875

**Effect of a non biologic treat-to-target strategy on MRI-determined inflammatory and destructive changes in early rheumatoid arthritis. Results from a 2-year investigator-initiated double-blind randomized controlled clinical trial.**

Møller-Bisgaard, S., Ejbjerg, B. J., Eshed, I., Hørslev-Petersen, K., Hetland, M. L., Jurik, A. G., Vallø, J., Thomsen, H., Torfing, T., Stengaard-Pedersen, K., Junker, P., Steen Krogh, N., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Svendsen, A. J., Tarp, U. & Pødenphant, J. & 3 flere, Pedersen, J. K., Lindegaard, H. M. & Østergaard, M., 2015.

**Impact of urate level on cardiovascular risk in allopurinol-treated patients: A nested case-control study**

Larsen, K. S., Pottegård, A., Lindegaard, H. M. & Hallas, J., 2015, I: *Pharmacoepidemiology and Drug Safety*. 24, S1, s. 351-352 2 s., 615.

**Impact of urate level on cardiovascular risk in allopurinol treated patients. A nested case control study**

Larsen, K. S., Pottegård, A., Lindegaard, H. M. & Hallas, J., 2015, I: *Annals of the Rheumatic Diseases*. 74, S2, s. 1208 1 s., AB0921.

**Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis**

Krol, A., Garred, P., Heegaard, N., Christensen, A. F., Hetland, M., Stengaard-Pedersen, K., Junker, P., Madsen, H., Lottenburger, T., Ellingsen, T., Andersen, L., Hansen, I., Pedersen, J., Svendsen, A. J., Tarp, U., Pødenphant, J., Lindegaard, H., Østergaard, M., Hørslev-Petersen, K. & Jacobsen, S., 2015, I: *Scandinavian Journal of Rheumatology*. 44, 1, s. 8-12

**Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO**

Glintborg, B., Gudbjornsson, B., Steen Krogh, N., Omerovic, E., Manilo, N., Holland-Fischer, M., Lindegaard, H. M., Gitte Loft, A., Nordin, H., Johnsen, L., Flejsborg Oeftiger, S. M., Hansen, A., Rasmussen, C., Grondal, G., Jon Geirsson, A. & Lund Hetland, M., nov. 2014, I: *Rheumatology*. 53, 11, s. 2100-2109

**A non-synonymous single-nucleotide polymorphism in the gene encoding Toll-like Receptor 3 (TLR3) is associated with sero-negative Rheumatoid Arthritis (RA) in a Danish population**

Laska, M. J., Hansen, B., Troldborg, A., Lorenzen, T., Stengaard-Pedersen, K., Junker, P., Nexø, B. A. & Lindegaard, H. M., 10. okt. 2014, I: *BMC Research Notes*. 7, 5 s., 716.

**Eosinophilia in routine blood samples as a biomarker for solid tumor development - A study based on the Copenhagen Primary Care Differential Count (CopDiff) Database**

Andersen, C. L., Siersma, V. D., Hasselbalch, H. C., Lindegaard, H., Vestergaard, H., Felding, P., de Fine Olivarius, N. & Bjerrum, O. W., 1. sep. 2014, I: *Acta Oncologica*. 53, 9, s. 1245-1250

**Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis**

Enevold, C., Baslund, B., Linde, L., Josephsen, N. L., Tarp, U., Lindegaard, H., Jacobsen, S. & Nielsen, C. H., aug. 2014, I: *Pharmacogenetics and Genomics*. 24, 8, s. 401-405

**Fast infusion of tocilizumab in rheumatoid arthritis is well tolerated**

Lindegaard, H. M., Johansen, P., Grøndal, G., Jensen, E. C. N., Juul, L., Schlemmer, A., Agular, B. M. & Jensen Hansen, I. M., 11. jun. 2014, I: *Annals of the Rheumatic Diseases*. 73, 2. Supplement, s. 493 1 s., FRI0299.

**Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting**

Andersen, C. L., Lindegaard, H., Vestergaard, H., Siersma, V. D., Hasselbalch, H. C., de Fine Olivarius, N., Bjerrum, O. W. & Junker, P., 10. jun. 2014, I: *PLOS ONE*. 9, 6, e99388.

**Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life: The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial**

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Podenphant, J., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Horn, H. C., Ammitzboll, C. G., Jørgensen, A., Krintel, S. B., Raun, J., Johansen, J. S., Østergaard, M., Stengaard-Pedersen, K. & OPERA Study Group, apr. 2014, I: *Annals of the Rheumatic Diseases*. 73, 4, s. 654-661 8 s.

**Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study**

Larsen, K. S., Pottegård, A., Lindegaard, H. M. & Hallas, J., 2014, I: *Pharmacoepidemiology and Drug Safety*. 23, S1, s. 44-45 81.

**Fast infusion of tocilizumab in rheumatoid arthritis is well tolerated.**

Lindegaard, H. M., Johansen, P., Grøndal, G., Jensen, E. C., Juul, L., Schlemmer, A. M., Agular, B. M. & Jensen Hansen, I. M., 2014.

**Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial**

Jensen, T. W., Hansen, M. S., Hørslev-Petersen, K., Hyldstrup, L., Abrahamsen, B., Langdahl, B. L., Zerahn, B., Pødenphant, J., Stengaard-Petersen, K., Junker, P., Ostergaard, M., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A. J. & Tarp, U. & 5 flere, Lindegaard, H., Jurik, A. G., Vestergaard, A., Hetland, M. L. & The CIMESTRA Study Group, 2014, I: *Annals of the Rheumatic Diseases*. 73, 6, s.

**Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression**

Ellingsen, T., Hansen, I., Thorsen, J., Møller, B. K., Tarp, U., Lottenburger, T., Andersen, L. S., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A. J., Lindegaard, H., Jacobsen, S., Østergaard, M., Vestergaard, A., Jurik, A. G., Junker, P., Christensen, A. F., Hetland, M. L. & Hørslev-Petersen, K. & 1 flere, Stengaard-Pedersen, K., 2014, I: *Scandinavian Journal of Rheumatology*. 43, 2, s. 91-100 10 s.

**Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor  $\alpha$  inhibitor therapy: Results from the Danish nationwide DANBIO registry**

Glintborg, B., Østergaard, M., Krogh, N. S., Tarp, U., Manilo, N., Loft, A. G. R., Hansen, A., Schlemmer, A., Fana, V., Lindegaard, H. M., Nordin, H., Rasmussen, C., Ejstrup, L., Jensen, D. V., Petersen, P. M. & Hetland, M. L., 17. sep. 2013, I: *Annals of the Rheumatic Diseases*. 72, 7, s. 1149-1155

**Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death.**

Lindegaard, H. M., 15. jun. 2013.

**Eosinophilia in Routine Blood Samples and the Subsequent Risk of Hemotological Malignancies and Death**

Andersen, C. L., Siersma, V. D., Hasselbalch, H. C., Lindegaard, H. M., Vestergaard, H., Felding, P., Olivarius, N. D. F. & Bjerrum, O. W., 14. jun. 2013.

**Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death**

Andersen, C. L., Siersma, V. D., Hasselbalch, H. C., Lindegaard, H., Vestergaard, H., Felding, P., de Fine Olivarius, N. & Bjerrum, O. W., 13. jun. 2013, I: *American Journal of Hematology*. 88, 10, s. 843-847

**Improved remission rates acquired by adding Adalimumab to Methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of Adalimumab. A 2-year investigator initiated randomised, controlled study on early rheumatoid arthritis**

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Pødenphant, J., Ellingsen, T. J., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I. T., Lottenburger, T., Jørgensen, A., Krintel, S. B., Raun, J. L., Ammitzbøll, C. G., Johansen, J. S., Østergaard, M. & Stengaard-Pedersen, K., 13. jun. 2013.

**Improved remission rates acquired by adding Adalimumab to Methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of Adalimumab. A 2-year investigator initiated randomised, controlled study on early rheumatoid arthritis**

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Pødenphant, J., Ellingsen, T. J., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I. T., Lottenburger, T., Jørgensen, A., Krintel, S. B., Raun, J. L., Ammitzbøll, C. G., Johansen, J. S., Østergaard, M. & Stengaard-Pedersen, K., jun. 2013.

**MicroRNA expression profiles as biomarkers for prediction of treatment response to adalimumab in patients with early rheumatoid arthritis**

Krintel, S. B., Dehlendorff, C., Hetland, M. L., Hørslev-Petersen, K., Andersen, K. K., Junker, P., Pødenphant, J., Ellingsen, T. J., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I. T., Horn, H. C., Jørgensen, A., Raun, J. L., Ammitzbøll, C. G., Østergaard, M. & Stengaard-Pedersen, K. & 1 flere, Johansen, J. S., jun. 2013. 1 s.

**A Treat-To-Target Strategy With Methotrexate And Intra-Articular Triamcinolone With Or Without Added Adalimumab Reduces Synovitis, Osteitis And Tenosynovitis And Halts Structural Damage Progression In Early Rheumatoid Arthritis: The OPERA Magnetic Resonance Imaging Sub-Study**

Bjørndal Axelsen, M., Eshed, I., Hørslev-Petersen, K., Stengaard-Pedersen, K., Hetland, M. L., M. Møller, J., Junker, P., Pødenphant, J., Ellingsen, T., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Yde Dam, M., Hansen, I., Horn, H. C., Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B. & Raun, J. & 3 flere, Johansen, J. S., Steen Krogh, N. & Østergaard, M., 2013.

**Circulating lung surfactant protein D (SP-D) differs between rheumatoid arthritis (RA) patients according to anti-citrullinated protein antibody (anti-CCP) and IgM-rheumafactor (IgM-RF) status**

Lindegaard, H. M., Hørslev-Petersen, K., Lorenzen, T., Raun, J., Jensen, L., Sørensen, G., Christensen, A. F. & Junker, P., 2013.

**Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor  $\alpha$  inhibitor therapy: results from the Danish Nationwide DANBIO Registry**

Glintborg, B., Ostergaard, M., Krogh, N. S., Andersen, M. D., Tarp, U., Loft, A. G., Lindegaard, H. M., Holland-Fischer, M., Nordin, H., Jensen, D. V., Olsen, C. H. & Hetland, M. L., 2013, *I: Arthritis & Rheumatism*. 65, 5, s. 1213-1223

**Genotypic and Haplotypic Effects of 7 Single-Nucleotide Poly-morphisms In the CRP Gene On Levels Of C-Reactive Protein and DAS28 In a Cohort Of 180 Untreated Newly Diagnosed Rheumatoid Arthritis Patients (OPERA Study)**

Ammitzbøll, C. G., Steffensen, R., Junker, P., Østergaard, M., Johansen, J. S., Pødenphant, J., Hetland, M. L., Lindegaard, H. M., Ellingsen, T. & Stengaard-Pedersen, K., 2013.

**Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis: Results From The Nationwide Registries Danbio and Icebio**

Glintborg, B., Gudbjørnsson, B., Steen Krogh, N., Omerovic, E., Manilo, N., Holland-Fischer, M., Lindegaard, H. M., Loft, A. G., Nordin, H., Johnsen, L., Flejsborg Oeftiger, S. M., Hansen, A., Rasmussen, C., Grondal, G., Jon Geirsson, A. & Hetland, M. L., 2013.

**Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry**

Ornbjerg, L. M., Ostergaard, M., Bøyesen, P., Krogh, N. S., Thormann, A., Tarp, U., Poulsen, U. E., Espesen, J., Ringsdal, V. S., Graudal, N. A., Kollerup, G. B., Jensen, D. V., Madsen, O. R., Glintborg, B., Christensen, T., Lindegaard, H., Dencker, D., Hansen, A., Andersen, A. R. & Hetland, M. L., 2013, *I: Annals of the Rheumatic Diseases*. 72, 1, s. 57-63 7 s.

**Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of adalimumab: A 2-year investigator initiated randomised, controlled study on early rheumatoid arthritis**

Hørslev-Petersen, K., Hetland, M., Junker, P., Pødenphant, J., Ellingsen, T. J., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M., Hansen, I., Lottenburger, T., Jørgensen, A., Krintel, S., Raun, J., Ammitzbøll, C. G., Johansen, J., Østergaard, M. & Stengaard-Pedersen, K., 2013.

**Incidences of overall and site specific cancers in TNF $\alpha$  inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry**

Dreyer, L., Mellekjær, L., Andersen, A. R., Bennett, P., Poulsen, U. E., Juulsgaard Ellingsen, T., Hansen, T. H., Jensen, D. V., Linde, L., Lindegaard, H. M., Loft, A. G. R., Nordin, H., Omerovic, E., Rasmussen, C., Schlemmer, A., Tarp, U. & Hetland, M. L., 2013, *I: Annals of the Rheumatic Diseases*. 72, 1, s. 79-82 4 s.

**Independent Of Induction Therapy With Adalimumab; Year 2 Clinical Results Of An Investigator-Initiated Randomised, Controlled Clinical Trial Of Early, Rheumatoid Arthritis (OPERA)**

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Pødenphant, J., Ellingsen, T., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Y. Dam, M., Hansen, I., Lottenburger, T., Jørgensen, A., Krintel, S. B., Raun, J., Ammitzbøll, C. G., Johansen, J., Østergaard, M. & Stengaard-Pedersen, K., 2013.

**Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab: Results Of a 2-Year Trial (OPERA)**

Hørslev-Petersen, K., Ornbjerg, L. M., Hetland, M. L., Junker, P., Pødenphant, J., Ellingsen, T., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Y. Dam, M., Hansen, I., Lottenburger, T., Jørgensen, A., Krintel, S. B., Raun, J., Ammitzbøll, C. G., Johansen, J., Østergaard, M. & Stengaard-Pedersen, K., 2013.

**MicroRNA expression profiles as biomarkers for prediction of treatment response to adalimumab in patients with early rheumatoid arthritis**

Krintel, S., Dehlendorff, C., Hetland, M., Hørslev-Petersen, K., Andersen, K., Junker, P., Pødenphant, J., Ellingsen, T. J., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M., Hansen, I., Horn, H. C., Jørgensen, A., Raun, J., Ammitzbøll, C., Østergaard, M. & Stengaard-Pedersen, K. & 1 flere, Johansen, J., 2013.



**MicroRNA Expression Profiles Associated With Response To Adalimumab and Methotrexate: A Placebo-Controlled Clinical Trial**

Krintel, S. B., Dehlendorff, C., Hetland, M. L., Hørslev-Petersen, K., Andersen, K., Junker, P., Pødenphant, J., Ellingsen, T., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Y. Dam, M., Hansen, I., Horn, H. C., Jørgensen, A., Raun, J., Ammitzbøll, C. G., Stengaard-Pedersen, K. & Johansen, J. S., 2013.

**Presence of antibodies to adalimumab and infliximab in patients with rheumatoid arthritis in clinical remission**

Eng, G., Fana, V., Omerovic, E., Højsgaard, P., Lindegaard, H. M., EK, J. & Bouchelouche, P., 2013.

**Rheumatoid arthritis and eosinophilia: The risk of lymphoproliferative malignancies and solid cancers: A study based on the Copenhagen primary care differential count (COPDIFF) database**

Lykkegaard Andersen, C., Vestergaard, H., Bjerrum, O., Siersma, V., Felding, P., Hasselbalch, H. C., de Fine Olivarius, N. & Lindegaard, H. M., 2013.

**Serious Adverse Events Associated With Using Biological Agents To Treat Rheumatoid Diseases: Network Meta-Analysis From a National Guideline Panel**

Tarp, S., Tarp, U., S. Andersen, L., Lorenzen, T., Lindegaard, H. M., Stoltenberg, M. B., S. Jensen, H., Brock, B., M. Mikkelsen, C., V. Jensen, D., Asmussen, K., Herlin, T. & Christensen, R., 2013.

**The Prevalence Of Biological Monotherapy Among Rheumatoid Arthritis Patients In Denmark: Results From The Danish Nationwide Danbio Registry**

Jørgensen, T. S., Kristensen, L. E., Lorenzen, T., Jensen, J., Zanjani, L., Laursen, T., Butt, S., Dam, M. Y., Lindegaard, H. M., Espesen, J., Hendricks, O., Kumar, P., Kincses, A., Larsen, L. H., Næser, E. K., V. Jensen, D., Grydehøj, J., Unger, B., Dufour, N. & Sørensen, V. N. & 4 flere, Vildhøj, S., Jensen Hansen, I. M., Raun, J. L. & Hetland, M. L., 2013, I: Arthritis & Rheumatism. 65, 1 s., 1478.

**Use of TNF inhibitors is associated with a reduced risk of diabetes in RA patients**

Lillegraven, S., Greenberg, J. & Lindegaard, H. M., 2013.

**Remission rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis: 1-year results of investigator-initiated, double-blinded randomized clinical trial**

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Pødenphant, J., Ellingsen, T. J., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I. T., Horn, H. C., Jørgensen, A., Krintel, S. B., Raun, J. L., Ammitzbøll, C. G., Johansen, J. S., Østergaard, M. & Stengaard-Pedersen, K., sep. 2012.

**The additive value of magnetic resonance imaging for bone edema in predicting rheumatoid arthritis development in early undifferentiated arthritis: comment on the article by Duer-Jensen et al Reply**

Duer-Jensen, A., Hetland, M. L., Hørslev-Petersen, K., Bak, L., Ejbjerg, B. J., Hansen, M. S., Johansen, J. S., Møller, J. M., Lindegaard, H. M., Vinterberg, H. & Østergaard, M., 1. jan. 2012, I: Arthritis & Rheumatism. 64, 1, s. 322-323 2 s.

**Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor alpha therapy: Results from The Danish Nationwide DANBIO Registry**

Glintborg, B., Østergaard, M., Krogh, N., Tarp, U., Loft, A., Hansen, A., Schlemmer, A., Fana, V., Kristensen, M., Lindegaard, H. M., Nordin, H., Rasmussen, C., Ejstrup, L., Petersen, P., Manilo, N., Jensen, D. & Hetland, M., 2012.

**Feasibility of a standardized ultrasound examination in patients with rheumatoid arthritis: A quality improvement among rheumatologists cohort.**

Ellegaard, K., Torp-Pedersen, S. T., Christensen, R., Stoltenberg, M., Hansen, A., Lorenzen, T., Jensen, D., Lindegaard, H. M., Juul, L., Røgind, H., Bülow, P., Chrysidis, S., Kowalski, M. R., Danneskiold-Samsøe, B. & Bliddal, H., 2012, I: BMC Musculoskeletal Disorders. 13, s. 35

**Impact of tumour necrosis factor inhibitor treatment on hand bone loss in rheumatoid arthritis patients treated in clinical practice. Results from the Nationwide Danish DANBIO Registry.**

Ørnberg, L. M., Østergaard, M., Bøyesen, P., Jensen, T., Thormann, A., Tarp, U., Böhme, W., Dencker, D., Lindegaard, H. M., Poulsen, U., Hansen, A., Ringsdal, V. S., Schlemmer, A., Graudal, N., Andersen, A., Espesen, J., Kollerup, G. B., Christensen, T., Pelck, R. & Glintborg, B. & 4 flere, Madsen, O., Jensen, D., Maigaard, O. & Hetland, M. L., 2012, I: Arthritis & Rheumatism. 72, 1, s. 57-63 7 s.

**Incidence of cancer in TNF inhibitor treated patients with rheumatoid arthritis and other types of arthritides: A follow-up study from the DANBIO Registry**

Dreyer, L., Møllekjær, L., Andersen, A., Bennett, P., Engling, U., Ellingsen, T., Hansen, T., Jensen, D., Linde, L., Lindegaard, H. M., Loft, A., Nordin, H., Omerovic, E., Rasmussen, C., Slemmer, A., Tarp, U. & Hetland, M., 2012.

**Predictors of radiographic progression in 940 rheumatoid arthritis patients during TNF-inhibitor treatment in clinical practice**

Ørnbjerg, L., Østergaard, M., Bøyesen, P., Thormann, A., Tarp, U., Poulsen, U., Graudal, N., Hansen, A., Espesen, J., Ringsdal, V., Schlemmer, A., Andersen, A., Kollerup, G., Glinthborg, B., Pelck, R., Christensen, T., Jensen, D., Madsen, O., Bøhme, W. & Dencker, D. & 2 flere, Lindegaard, H. M. & Hetland, M., 2012.

**REMISSION RATES INCREASE SUBSTANTIALLY BY ADDING ADALIMUMAB TO METHOTREXATE AND INTRA-ARTICULAR GLUCOCORTICOID IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS - 1-YEAR RESULTS OF INVESTIGATOR INITIATED, DOUBLE-BLINDED RANDOMIZED CLINICAL TRIAL**

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Pødenphant, J., Ellingsen, T. J., Ahlquist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I. T., Horn, H. C., Jørgensen, A., Krintel, S. B., Raun, J. L., Ammitzbøll, C. G., Johansen, J. S., Østergaard, M. & Stengaard-Pedersen, K., 2012.

**REMISSION RATES INCREASE SUBSTANTIALLY BY ADDING ADALIMUMAB TO METHOTREXATE AND INTRA-ARTICULAR GLUCOCORTICOID IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS - 1-YEAR RESULTS OF INVESTIGATOR-INITIATED DOUBLE BLINDED RANDOMIZED CLINICAL TRIAL (OPER<)**

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Pødenphant, J., Ellingsen, T. J., Ahlquist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I. T., Horn, H. C., Jørgensen, A., Krintel, S. B., Raun, J. L., Ammitzbøll, C. G., Johansen, J. S., Østergaard, M. & Stengaard-Pedersen, K., 2012, I: Annals of the Rheumatic Diseases. 71, suppl 3, s. 360 2 s.

**Risk factors for radiographic progression during TNF-inhibitor treatment in 932 rheumatoid arthritis patients treated in clinical practice: Results from the Nationwide Danish DANBIO Registry**

Ørnbjerg, L. M., Østergaard, M., Bøyesen, P., Jensen, T., Tarp, U., Bøhme, W., Dencker, D., Lindegaard, H. M., Poulsen, U., Hansen, A., Ringsdal, V. S., Schlemmer, A., Graudal, N., Andersen, A., Espesen, J., Kollerup, G. B., Christensen, T., Pelck, R., Glinthborg, B. & Madsen, O. & 3 flere, Jensen, D., Maigaard, O. & Hetland, M. L., 2012, I: Arthritis & Rheumatism. 64 , Suppl, s. S157

**Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP**

Hetland, M. L., Østergaard, M., Ejbjerg, B., Jacobsen, S. K., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Hansen, I. T., Andersen, L. S., Tarp, U., Svendsen, A. J., Pedersen, J. K., Skjødt, H., Ellingsen, T. J., Lindegaard, H., Pødenphant, J., Hørslev-Petersen, K. & The CIMESTRA Study Group, 2012, I: Annals of the Rheumatic Diseases. 71, 6, s. 851-6 6 s.

**Using MRI Synovitis to count involved Joints in the ACR/EULAR 2010 RA criteria increases their sensitivity and specificity**

Anne, D.-J., Hørslev-Petersen, K., Bak, L., Johansen, J. S., Hansen, M. S., Hetland, M. L., Ejbjerg, B. J., Lindegaard, H. M., Vinterberg, H., Møller, J. & Østergaard, M., 2012.

**Using MRI synovitis to count involved joints in the ACR/EULAR 2010 RA criteria increases their sensitivity and specificity**

Duer-Jensen, A., Hørslev-Petersen, K., Bak, L., Johansen, J., Hansen, M., Hetland, M., Ejbjerg, B., Lindegaard, H. M., Vinterberg, H., Møller, J. & Østergaard, M., 2012.

**Using MRI Synovitis to count involved Joints in the ACR/EULAR 2010 RA criteria increases their Sensitivity and Specificity**

Duer-Jensen, A., Hørslev-Petersen, K., Bak, L., Johansen, J. S., Hansen, M. S., Hetland, M. L., Ejbjerg, B. J., Lindegaard, H. M., Vinterberg, H., Møller, J. & Østergaard, M., 2012, I: Annals of the Rheumatic Diseases. 71, suppl 3, s. 601 1 s.

**Short- and Long-Term Effect of Unguided, Intra-Articular Injections with Betamethasone In Early Rheumatoid Arthritis: Impact of Joint Area, Repeated Injections, MRI Findings, Anti-CCP, IgM-RF and CRP.**

Hetland, M. L., Østergaard, M., Ejbjerg, B. J., Jacobsen, S., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Hansen, I., Andersen, L. S., Tarp, U., Svendsen, A. J., Pedersen, J. K., Skjødt, H., Ellingsen, T., Lindegaard, H. M. &

Hørslev-Petersen, K., 5. nov. 2011, *Arthritis & Rheumatism: Abstract Supplement, 2011 Annual Scientific Meeting.* s. 493-493

**Adalimumab Added to Methotrexate an Intra-Articular Glucocorticoid Increases Remission Rates At One Year In Early, DMARD-Naïve Patients with Rheumatoid Arthritis - An Investigator-Initiated Randomized, Controlled, Double-Blinded Study.**

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Pødenphant, J., Ellingsen, T., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Horn, H. C., Jørgensen, A., Krintel, S. B., Raun, J., Ammitzbøll, C. G., Johansen, J., Østergaard, M. & Stengaard-Pedersen, K., 4. nov. 2011, *Arthritis & Rheumatism: Abstract Supplement, 2011 Annual Scientific Meeting.* s. 147-147

**Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis**

Duer-Jensen, A., Hørslev-Petersen, K., Hetland, M. L., Bak, L., Ejbjerg, B. J., Hansen, M. S., Johansen, J. S., Lindegaard, H. M., Vinterberg, H., Møller, J. M. & Østergaard, M., 1. aug. 2011, I: *Arthritis & Rheumatism.* 63, 8, s. 2192-202 11 s.

**Tumornekrosefaktor-alfa-inhibitorer er glukokortikoidbesparende hos patienter med reumatoid arthritis**

Nilsson, A. C., Christensen, A. F., Junker, P. & Lindegaard, H. M., 2011, I: *Ugeskrift for Læger.* 173, 16

**Tumour necrosis factor- $\alpha$  inhibitors are glucocorticoid-sparing in rheumatoid arthritis**

Nilsson, A. C., Christensen, A. F., Junker, P. & Lindegaard, H. M., 2011, I: *Danish Medical Bulletin.* 58, 4, s. A4257

**MRI Bone Edema Is an Independent Predictor of Development of Rheumatoid Arthritis in Patients with Early Undifferentiated Arthritis**

Duer-Jensen, A., Hørslev-Petersen, K., Hetland, M. L., Bak, L., Ejbjerg, B., Hansen, M. S., Johansen, J. S., Lindegaard, H. M., Vinterberg, H., Møller, J. M. & Østergaard, M., nov. 2010.

**Reply**

Hetland, M. L., Linde, L., Christensen, I. J., Dreyer, L., Tarp, U., Hansen, A., Hansen, I. T., Kollerup, G., Lindegaard, H. M., Poulsen, U. E., Schlemmer, A., Jensen, D. V., Jensen, S., Hostenkamp, G. & Østergaard, M., sep. 2010, I: *Arthritis & Rheumatism.* 62, 9, s. 2826-2828

**Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides**

Christensen, A. F., Hørslev-Petersen, K., Christgau, S., Lindegaard, H. M., Lottenburger, T., Junker, K., Hetland, M. L., Stengaard-Pedersen, K., Jacobsen, S., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A. J., Tarp, U., Pødenphant, J., Heegaard, N. H. H. & Vestergaard, A. & 3 flere, Jurik, A. G., Østergaard, M. & Junker, P., 1. jun. 2010, I: *The Journal of Rheumatology.* 37, 6, s. 1113-20

**Circulating surfactant protein -D is low and correlates negatively with systemic inflammation in early, untreated rheumatoid arthritis**

Christensen, A. F., Sørensen, G. L., Hørslev-Petersen, K., Holmskov, U., Lindegaard, H. M., Junker, K., Hetland, M. L., Stengaard-Pedersen, K., Jacobsen, S., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A., Tarp, U., Pødenphant, J. & Vestergaard, A. & 3 flere, Jurik, A. G., Østergaard, M. & Junker, P., 8. mar. 2010, I: *Arthritis Research & Therapy.* 12, 2, s. R39

**Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry**

Hetland, M. L., Christensen, I. J., Tarp, U., Dreyer, L., Hansen, A., Hansen, I. T., Kollerup, G., Linde, L., Lindegaard, H. M., Poulsen, U. E., Schlemmer, A., Jensen, D. V., Jensen, S., Hostenkamp, G. & Østergaard, M., 1. jan. 2010, I: *Arthritis & Rheumatism.* 62, 1, s. 22-32 10 s.

**Circadian pattern and the effect of standardized physical exercise on procollagen IIA N-peptide (PIIANP) in rheumatoid arthritis at different stages and in healthy individuals**

Christensen, A. F., Lottenburger, T., Lindegaard, H. M., Junker, K., Hørslev-Petersen, K. & Junker, P., 2010, I: *Biomarkers.* 15, 1, s. 80-85

**Impact of drug discontinuation on radiographic progression 2 years after initiation of TNF-inhibitor treatment in clinical practice**

Ørnbjerg, L., Østergaard, M., Bøyesen, P., Thormann, A., Tarp, U., Böhme, W., Dencker, D., Lindegaard, H. M., Poulsen, U. E., Hansen, A., Ringsdal, V., Schlemmer, A., Graudal, N., Andersen, A., Espesen, J., Kollerup, G., Christensen, T., Pelck, R., Glinborg, B. & Madsen, O. & 3 flere, Jensen, D., Majgaard, O. & Hetland, M., 2010, I: *Annals of the Rheumatic Diseases*. 69, suppl 3, s. 459

**Impact of TNF-inhibitor treatment on radiographic joint destruction in rheumatoid arthritis patients treated in clinical practice**

Ørnbjerg, L., Østergaard, M., Thormann, A., Bøyesen, P., Tarp, U., Böhme, W., Dencker, D., Lindegaard, H. M., Poulsen, U. E., Hansen, A., Ringsdal, V., Schlemmer, A., Graudal, N., Andersen, A., Espesen, J., Kollerup, G., Christensen, T., Pelck, R., Glinborg, B. & Madsen, O. & 3 flere, Jensen, D., Majgaard, O. & Hetland, M. L., 2010, I: *Annals of the Rheumatic Diseases*. 69, suppl 3, s. 142

**Mannose-binding lectin gene polymorphisms are associated with disease activity and physical disability in untreated, anti-cyclic citrullinated peptide-positive patients with early rheumatoid arthritis**

Jacobsen, S., Garred, P., Madsen, H. O., Heegaard, N. H. H., Hetland, M. L., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Ellingsen, T., Smedegaard Andersen, L., Hansen, I., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A. J., Tarp, U., Pødenphant, J., Lindegaard, H., Vestergaard, A. & Østergaard, M. & 1 flere, Hørslev-Petersen, K., 1. apr. 2009, I: *The Journal of Rheumatology*. 36, 4, s. 731-5 4 s.

**Karotinaemi hos patient med excessivt betakarotinfødeindtag og dysreguleret diabetes mellitus.**

Mikkelsen, C. S., Mikkelsen, D. B. & Lindegaard, H. M., 26. jan. 2009, I: *Ugeskrift for Læger*. 171, 5, s. 315-6 1 s.

**Månedens billede: Arm edema**

Mikkelsen, C. S., Justesen, P. & Lindegaard, H. M., 12. jan. 2009, I: *Ugeskrift for Læger*. 171, 3, s. 146

**Different Cartilage Oligomeric Matrix Protein (COMP) Patterns in Untreated Anti-CCP Positive and Negative Rheumatoid Arthritis (RA).**

Christensen, A. F., Junker, P., Lindegaard, H. M., Lottenburger, T., Ejbjerg, B., Hetland, M. L., Stengaard-Pedersen, K., Jacobsen, S., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J., Lauridsen, U., Svendsen, A., Tarp, U., Pødenphant, J., Jurik, A., Østergaard, M. & Hørslev-Petersen, K., 2009.

**Differential association of the N-propeptide of collagen IIA (PIIANP) and collagen II C-telopeptide (CTX-II) with synovitis and erosions in early and longstanding rheumatoid arthritis**

Christensen, A. F., Lottenburger, T., Lindegaard, H., Christgau, S., Hørslev-Petersen, K. & Junker, P., 2009, I: *Clinical and Experimental Rheumatology*. 27, 2, s. 307-14 7 s.

**Direct Comparison of 4 Years' Drug Survival of Adalimumab, Etanercept and Infliximab in Rheumatoid Arthritis Patients. An Observational Study From the DANBIO Registry.**

Hetland, M. L., Christensen, I. J., Tarp, U., Dreyer, L., Hansen, A., Hansen, I. T., Kollerup, G., Linde, L., Lindegaard, H. M., Poulsen, U. E., Schlemmer, A., Jensen, D. V., Jensen, S. & Østergaard, M., 2009.

**Predictors of Radiographic Joint Destruction in Rheumatoid Arthritis Patients During TNF-Inhibitor Treatment in Clinical Practice.**

Ørnbjerg, L. M., Østergaard, M., Bøyesen, P., Thormann, A., Tarp, U., Røgind, H., Böhme, W., Lindegaard, H. M., Poulsen, U., Hansen, A., Ringsdal, V., Graudal, N., Andersen, A. R., Espesen, J., Kollerup, G., Christensen, T. G., Pelck, R., Madsen, O. R., Jensen, D. V. & Majgård, O. & 1 flere, Hetland, M. L., 2009.

**Standardized Ultrasound Examination of the Hand in Patients with Rheumatoid Arthritis - a Multicentre Learning Experience: Education in Ultrasound of rheumatoid Arthritis - EURA.**

Ellegaard, K., Torp-Pedersen, S., Christensen, R., Stoltenberg, M., Hansen, A., Lorenzen, T., Jensen, D., Lindegaard, H. M., Juul, L., Røgind, H., Bülow, P., Chrysidis, S., Kowalski, M., Danneskiold-Samsøe, B. & Bliddal, H., 2009.

**TNF-inhibitors reduce radiographic joint destruction by 65 % in rheumatoid arthritis patients treated in clinical practice: Results from the nationwide Danish DANBIO registry**

Østergaard, M., Ørnbjerg, L., Bøysen, P., Thorman, A., Tarp, U., Røtgind, H., Böhme, W., Lindegaard, H. M., Poulsen, U., Hansen, A., Ringsdal, V., Graudal, N., Andersen, A., Espesen, J., Stoltenberg, M., Kollerup, G., Christensen, T., Pelck, R., Madsen, O. & Jensen, D. & 2 flere, Majgaard, O. & Hetland, M., 2009.

**Uncoupling of collagen II Metabolism in Newly-diagnosed Rheumatoid Arthritis (RA) Is Linked to Inflammation and Antibodies against Cyclic Citrullinated Peptides.**

Christensen, A. F., Junker, P., Lindegaard, H. M., Christgau, S., Lottenburger, T., Hetland, M. L., Stengaard-Pedersen, K., Jacobsen, S., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J., Lauridsen, U., Svendsen, A., Tarp, U., Pødenphant, J., Jurik, A., Østergaard, M. & Hørslev-Petersen, K., 2009.

**Rygning—en risikofaktor for udvikling af reumatoid arthritis.**

Christensen, A. F., Lindegaard, H. M. & Junker, P., 8. sep. 2008, I: Ugeskrift for Læger. 170, 37, s. 2864-9 5 s.

**Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.**

Hetland, M., Lindegaard, H. M., Hansen, A., Pødenphant, J., Unkerskov, J., Ringsdal, V., Østergaard, M. & Tarp, U., 1. jul. 2008, I: Annals of the Rheumatic Diseases. 67, 7, s. 1023-6 3 s.

**MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis: Results from a 2 year randomized controlled trial (CIMESTRA).**

Hetland, M. L., Ejbjerg, B. J., Hørslev-Petersen, K., Jacobsen, S., Vestergaard, A., Jurik, A. G., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Hansen, I., Andersen, L. S., Tarp, U., Skjødt, H., Pedersen, J. K., Majgaard, O., Svendsen, A. J., Ellingsen, T., Lindegaard, H. M., Christensen, A. F. & Vallø, J. & 4 flere, Torfing, T., Narvestad, E., Thomsen, H. S. & Østergaard, M., 3. apr. 2008, I: Annals of the Rheumatic Diseases. 68, 3, s. 384-390

**Circulating surfactant protein D is decreased in early rheumatoid arthritis: A 1-year prospective study**

Høgh, S. V., Lindegaard, H. M., Sørensen, G. L., Høj, A., Bendixen, C., Junker, P. & Holmskov, U., 1. jan. 2008, I: Scandinavian Journal of Immunology. 67, 1, s. 71-76 5 s.

**Circulating type IIA procollagen N-propeptide (PIIANP) is decreased in early rheumatoid arthritis (RA)**

Christensen, A. F., Junker, P., Lindegaard, H. M., Sørensen, G., Holmskov, U., Hetland, M., Stengaard-Pedersen, K., Lottenburger, T., Ellingsen, T., Andersen, L., Hansen, I., Skjødt, H., Pedersen, J., Lauridsen, U., Svendsen, A. J., Tarp, U., Pødenphant, J., Vestergaard, A., Jurik, A. & Østergaard, M. & 1 flere, Hørslev-Petersen, K., 2008.

**Aggressive combination therapy with intraarticular glucocorticoid injections and conventional DMARDs in early rheumatoid arthritis: Two Year Clinical and Radiographic Results From The CIMESTRA Study**

Hetland, M. L., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Hansen, I., Andersen, L. S., Tarp, U., Svendsen, A., Pedersen, J. K., Skjødt, H., Lauridsen, U. B., Ellingsen, T., van Overeem Hansen, G., Lindegaard, H., Vestergaard, A., Jurik, A. G., Østergaard, M. & Hørslev-Petersen, K., 18. sep. 2007, I: Annals of the Rheumatic Diseases.

**Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?**

Hjardem, E., Østergaard, M., Pødenphant, J., Tarp, U., Andersen, L. S., Bing, J., Peen, E., Lindegaard, H. M., Ringsdal, V. S., Rødgaard, A., Skøt, J., Hansen, A., Mogensen, H. H., Unkerskov, J. & Hetland, M. L., 1. mar. 2007, I: Annals of the Rheumatic Diseases. 66, 9, s. 1184-1189

**Associations between anti-CCP, shared epitope and erosive disease at onset of rheumatoid arthritis are dominant in smoking patients**

Jacobsen, S., Garred, P., Madsen, H. O., Svejgaard, A., Heegaard, N., Christensen, A. F., Hetland, M. L., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A. J., Tarp, U., Pødenphant, J. & Hansen, G. & 4 flere, Lindegaard, H. M., de Carvalho, A., Østergaard, M. & Hørslev-Petersen, K., 2007.

**Is it possible to stop radiographic progression with conventional treatment in early rheumatoid arthritis? 2 years results from the CIMESTRA study**

Hetland, M., Østergaard, M., Vestergaard, A., Jurik, A., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Hansen, I., Andersen, L., Tarp, U., Skjødt, H., Pedersen, J., Majgaard, O., Svendsen, A. J., Ellingsen, T., Hansen, G., Lindegaard, H. M. & Hørslev-Petersen, K., 2007, I: *Annals of the Rheumatic Diseases*. suppl II, s. 91

**Mannose binding lectin gene polymorphisms are associated with disease activity and functional disability in untreated, anti-CCP positiv early rheumatoid arthritis patients**

Jacobsen, S., Garred, P., Madsen, H. O., Svejgaard, A., Heegaard, N., Hetland, M. L., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A. J., Tarp, U., Pødenphant, J., Hansens, G. & Lindegaard, H. M. & 3 flere, de Carvalho, A., Østergaard, M. & Hørslev-Petersen, K., 2007.

**Mannose binding lectin gene polymorphisms are associated with disease activity and functional disability in untreated, anti-CCP positive early rheumatoid arthritis patients**

Jacobsen, S., Garred, P., Madsen, H. O., Svejgaard, A., Heegaard, N., Hetland, M. L., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A. J., Tarp, U., Pødenphant, J., Hansen, G. & Lindegaard, H. M. & 3 flere, de Carvalho, A., Østergaard, M. & Hørslev-Petersen, K., 2007. 1 s.

**MRI Bone Oedema is the Strongest Predictor of Subsequent Radiographic Progression in Early RA: Results from a 2 Year Randomized Controlled Trial (CIMESTRA)**

Hetland, M. L., Ejbjerg, B., Østergaard, M., Jacobsen, S., Vestergaard, A., Jurik, A. G., Stengaard Andersen, K., Junker, P., Lottenburger, T., Hansen, I., Andersen, L. S., Tarp, U., Skjødt, H., Pedersen, J. K., Majgaard, O., Svendsen, A. J., Ellingsen, T., Hansen, G., Lindegaard, H. M. & Vallø, J. & 3 flere, Torfing, T., Thomsen, H. S. & Hørslev-Pedersen, K., 2007, I: *Arthritis & Rheumatism*. 56, 9, s. 831 1 s.

**Patients with active, early rheumatoid arthritis had increased plasma-CXCL12 independent of disease activity and response to DMARD-treatment**

Hansen, I. T., Ellingsen, T., Jørgensen, A., Lottenburger, T., Hetland, M. L., Junker, P., Andersen, L. S., Lauridsen, U. B., Svendsen, A. J., Tarp, U., Hansen, G., Lindegaard, H. M., Carvalho, A. D., Østergaard, M., Hørslev-Petersen, K. & Stengaard-Pedersen, K., 2007.

**Serum IL-6 and YKL-40 Levels in Early Rheumatoid Arthritis are Associated with Disease Activity: Treatment Response and Radiographic Outcome**

Knudsen, L. S., Johansen, J. S., Christensen, I. J., Hetland, M. L., Jacobsen, S., Østergaard, M., Nielsen, H. J., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A. J., Tarp, U., Pødenphant, J. & Hansen, G. & 2 flere, Lindegaard, H. M. & Hørslev-Pedersen, K., 2007, I: *Arthritis & Rheumatism*. 56, 9, s. 721 1 s.

**Serum VEGF as a predictor of 2-year clinical outcome in early rheumatoid arthritis**

Hetland, M., Johansen, J. S., Østergaard, M., Nielsen, H. J., Jacobsen, S., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Svendsen, A. J., Tarp, U., Hansen, G., Lindegaard, H. M. & Hørslev-Petersen, K., 2007.

**Surfactant Protein-D (SP-D) is decreased in early, untreated rheumatoid arthritis**

Christensen, A. F., Holmskov, U., Sørensen, G., Lindegaard, H. M., Junker, P., Hetland, M., Stengaard-Pedersen, K., Jacobsen, S., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J., Lauridsen, U. B., Svendsen, A. J., Tarp, U., Pødenphant, J., Hansen, G. & Carvalho, A. & 2 flere, Østergaard, M. & Hørslev-Petersen, K., 2007.

**Temporal decrease in circulation type IIA procollagen N-peptide (PIIANP) in rheumatoid arthritis**

Christensen, A. F., Lottenburger, T., Lindegaard, H. M., Hørslev-Petersen, K. & Junker, P., 2007, I: *Arthritis & Rheumatism*. 56, s. 571-571

**Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study**

Hetland, M. L., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A., Tarp, U., Pødenphant, J., Hansen, G., Lindegaard, H., de Carvalho, A., Østergaard, M., Hørslev-Petersen, K. & Study Group, C., 1. maj 2006, I: *Arthritis & Rheumatism*. 54, 5, s. 1401-1409 8 s.

### **Behandling af reumatologiske patienter med biologiske præparater**

Lindegaard, H. M., Hetland, M., Tarp, U. & Hansen, A., 2006, *Danbio årsrapport 2000-2005*. 1. udgave udg. København: Institut for Rationel Farmacoterapi

### **Low-cost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: A 1-year follow-up study**

Lindegaard, H. M., Valloe, J., Hørslev-Petersen, K., Junker, P. & Østergaard, M., 2006, I: *Annals of the Rheumatic Diseases*. 65, 9, s. 1208-1212 4 s.

### **Plasma IL-6 in early rheumatoid arthritis is associated with disease activity, joint destruction, and treatment response**

Knudsen, L. S., Johansen, J. S., Hetland, M. L., Jacobsen, S., Østergaard, M., Nielsen, H. J., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A., Tarp, U., Pødenphant, J., Hansen, G. & Lindegaard, H. M. & 2 flere, Carvalho, A. & Hørslev-Petersen, K., 2006, *Ikke angivet*. EULAR Congress

### **(261/261) Do Early Changes in Serum and Plasma Vascular Endothelial Growth Factor (s-VEGF) Predict Long-Term Outcome in Newly Onset Rheumatoid Arthritis**

Hetland, M. L., Johansen, J. S., Østergaard, M., Nielsen, H. J., Jacobsen, S., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A., Tarp, U., Pødenphant, J., Hansen, G., Lindegaard, H. M. & Hørslev-Petersen, K., 2005.

### **Hurtig henvisning og behandling af patienter med akut Arthritis. Erfaringer fra 2 synovitklinikker**

Lindegaard, H. M., Hørslev-Petersen, K. & Junker, P., 2005, I: *Ugeskrift for Læger*. 167, s. 4458-61

### **[OP0099] No additional effect of cyclosporine on MRI-determined synovitis and bone damage in early rheumatoid arthritis treated with methotrexate and intraarticular betamethasone - results from a 12-months randomized double-blind placebocontrolled trial**

Ejbjerg, B. J., Østergaard, M., Jurik, A. G., Vallø, J., Thomsen, H. S., Torfing, T., Carvalho, A., Hetland, M. L., Steengaard-Petersen, K., Junker, P., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Lauridsen, U. B., Svendsen, A., Tarp, U., Pødenphant, J. & Hansen, G. & 3 flere, Pedersen, J. K., Lindegaard, H. M. & Hørslev-Petersen, K., 2005.

### **[THU0222] Baseline plasma and serum VEGF in early RA: Relation to treatment response and radiographic status one year later**

Hetland, M. L., Johansen, J. S., Østergaard, M., Nielsen, H., Stengaard-Pedersen, K., Junker, P., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjødt, H., Pedersen, J. K., Jacobsen, S., Svendsen, A., Tarp, U., Pødenphant, J., Hansen, G., Lindegaard, H. M. & Hørslev-Petersen, K., 2005.

### **[THU0321] Circulating connective tissue metabolites in very early rheumatoid arthritis**

Lottenburger, T., Junker, P., Junker, K., Hetland, M. L., Steengaard-Pedersen, K., Hansen, I., Andersen, L. S., Ellingsen, T., Tarp, U., Skjødt, H., Pedersen, J. K., Lauridsen, U. B., Svendsen, A., Pødenphant, J., Hansen, G., Lindegaard, H. M., Østergaard, M. & Hørslev-Petersen, K., 2005.

### **Early rheumatoid arthritis: Clinical aspects, skeletal imaging and studies on joint related extracellular matrix metabolism**

Lindegaard, H. M., 2002

### **Low field dedicated magnetic resonance imaging in untreated rheumatoid arthritis of recent onset**

Lindegaard, H., Vallø, J., Hørslev-Petersen, K., Junker, P. & Østergaard, M., 2001, I: *Annals of the Rheumatic Diseases*. 60, s. 770-776

## **Aktiviteter**

### **Tensor på Master Thesis: Association between body composition and course and rheumatoid arthritis. (Risk of developing rheumatoid arthritis, disease activity and radiographic progression).**

Lindegaard, H. M. (Tensor)

23. apr. 2013

**DIRF: Hjertesygdomme hos patienter med reumatoid artrit set i et tværfagligt perspektiv**

Lindegaard, H. M. (Oplægsholder)

11. apr. 2013

**DANBIO Årsrapport for 2012**

Lindegaard, H. M. (Arrangør)

8. mar. 2013

**DANBIO kursus**

Lindegaard, H. M. (Arrangør)

1. feb. 2013

**FNUG: Den gode konsultation**

Lindegaard, H. M. (Deltager)

1. feb. 2013

**Retslægerådet (Ekstern organisation)**

Lindegaard, H. M. (Medlem)

2012 → ...

**RADS Fagudvalg for Biologisk Behandling af Reumatologiske Lidelser (Ekstern organisation)**

Lindegaard, H. M. (Medlem)

2011 → ...

**Videreuddannelsesudvalget i Region Syddanmark Intern medicin:reumatologi. (Ekstern organisation)**

Lindegaard, H. M. (Medlem)

2011 → ...

**Bestået EULAR online eksamen**

Lindegaard, H. M. (Deltager)

1. okt. 2010

**RADS Fagudvalg for Biologisk Behandling af Reumatologiske Lidelser (Ekstern organisation)**

Lindegaard, H. M. (Medlem)

1. okt. 2010 → ...

**H-blok kursus for reumatologer**

Lindegaard, H. M. (Oplægsholder)

20. sep. 2010

**H-blok kursus for reumatologer**

Lindegaard, H. M. (Oplægsholder)

10. sep. 2010

**H-blok kursus for Øjenlæger**

Lindegaard, H. M. (Oplægsholder)

1. sep. 2010

**Videreuddannelsesudvalget i Region Syddanmark (Ekstern organisation)**

Lindegaard, H. M. (Medlem)

1. jul. 2010 → ...



**Staffmeeting.**

Lindegaard, H. M. (Foredragsholder)  
25. sep. 2009

**Masteruddannelsen Folkesundhed og Sygdomslære**

Lindegaard, H. M. (Andet)  
1. sep. 2009 → ...

**3e initiative in Rheumatology 2008-2009. How to investigate and follow-up undifferentiated peripheral inflammatory arthritis? (Ekstern organisation)**

Lindegaard, H. M. (Medlem)  
1. sep. 2008 → ...

**Retslægerådet (Ekstern organisation)**

Lindegaard, H. M. (Medlem)  
1. aug. 2008 → ...

**Dansk Meidicinsk Selskab (Ekstern organisation)**

Lindegaard, H. M. (Medlem)  
1. apr. 2008 → ...

**Dansk Reumatologisk Selskab, møde- og efteruddannelsesudvalget. (Ekstern organisation)**

Lindegaard, H. M. (Medlem)  
1. apr. 2008 → ...

**Advisory Board: BMS Abatacept behandling af patienter med reumatoid arthritis**

Lindegaard, H. M. (Rådgiver)  
1. jan. 2008 → ...

**Advisory board: Roche Tocilizumab (II-6 receptor antagonist) og Rituximab behandling af patienter med reumatoid arthritis.**

Lindegaard, H. M. (Rådgiver)  
1. jan. 2008 → ...

**Amgnos fagudvalg for TNF-alfa-hæmmer behandling i Danmark (Ekstern organisation)**

Lindegaard, H. M. (Medlem)  
1. jan. 2008 → ...

**Danbio Styregruppe (Ekstern organisation)**

Lindegaard, H. M. (Medlem)  
1. jan. 2008 → ...

**Dansk Reumatologisk Selskab (Ekstern organisation)**

Lindegaard, H. M. (Medlem)  
1. apr. 2007 → ...